East Tennessee State University

Digital Commons @ East Tennessee
State University
Electronic Theses and Dissertations

Student Works

12-2022

Folic Acid – Carbon Dots – Doxorubicin Nanoparticles as Cancer
Theranostic
Michael Tetteh
East Tennessee State University

Follow this and additional works at: https://dc.etsu.edu/etd
Part of the Organic Chemistry Commons

Recommended Citation
Tetteh, Michael, "Folic Acid – Carbon Dots – Doxorubicin Nanoparticles as Cancer Theranostic" (2022).
Electronic Theses and Dissertations. Paper 4160. https://dc.etsu.edu/etd/4160

This Thesis - unrestricted is brought to you for free and open access by the Student Works at Digital Commons @
East Tennessee State University. It has been accepted for inclusion in Electronic Theses and Dissertations by an
authorized administrator of Digital Commons @ East Tennessee State University. For more information, please
contact digilib@etsu.edu.

Folic Acid – Carbon Dots – Doxorubicin Nanoparticles as Cancer Theranostic
________________________
A thesis
presented to
the faculty of the Department of Chemistry
East Tennessee State University

In partial fulfillment
of the requirements for the degree
Master of Science in Chemistry
______________________
by
Michael Tawiah Tetteh
December 2022
_____________________
Dr. Robert Standaert, Chair
Dr. Hua Mei
Dr. Catherine McCusker
Dr. Aleksey Vasiliev

Keywords: Carbon dots, folic acid, doxorubicin, gemcitabine, nanoparticles, folate targeting

ABSTRACT
Folic Acid – Carbon Dots – Doxorubicin Nanoparticles as Cancer Theranostic
by
Michael Tawiah Tetteh

This work focused on engineering bi-functionalized nanoparticles (NPs) based on carbon dots
(CDs) to improve early cancer detection and treatment. Therefore, using folic acid (FA) as a
targeting agent, the CDs were prepared to deliver high concentrations (HC) of doxorubicin
(DOX) and gemcitabine (GEM) covalently and non-covalently to cancer cells. The prepared FACDs-DOX/GEM-HC NPs were characterized using ultraviolet-visible spectroscopy, fluorescence
spectroscopy, and Fourier transform infrared spectroscopy. Assessment of the drug loading
capacity (DLC) and drug loading efficiency (DLE) indicated that the non-covalent NPs have low
DLC but high DLE compared to the relatively low DLE and high DLC of covalent NPs. In vitro
drug release studies showed that the DOX/GEM release rate was faster at pH 5.0 in the noncovalent FA-CDs-DOX/GEM-HC NPs than covalent. Also, the non-covalent FA-CDs-DOX-HC
NPs showed greater percentage cumulative drug release and lower cell viability in the
MDA-MB-231 breast cancer cell line compared to covalent.
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CHAPTER 1. INTRODUCTION
Cancer is a genetic disease caused by abnormal proliferative cell growth. According to
the WHO statistics, cancer is the second paramount cause of death globally, with around 10
million deaths per year with a prediction of 29.5 million deaths estimated by 2040.1 This
anomalous prevalence rate and mortality has generated issues of great concern and poses a
significant threat to the medical regime. Various methods have been developed over the years to
detect and cure cancer, however, these methods are not always effective and are often
accompanied by unbearable side effects.2 As a result, early detection and new treatments of
cancer need to be developed.
Cancer Early Detection
Detecting cancer at its early stage greatly increases the chances for successful treatment.3
Early cancer detection is based on two distinct approaches namely, early diagnosis and
screening. The early diagnosis of cancer is aimed at diagnosing cancer when it is still in stage I
(early phase). One way that early diagnosis helps to improve cancer outcomes is through
awareness creation and public education on the dangers associated with cancer. For example,
people should be well informed about some common symptoms that could accompany the onset
of cancer such as breast lumps, blood-tinged saliva, and change in bowel habits. They should be
encouraged to seek medical advice when they begin to notice such symptoms. Also, barriers that
impede cancer diagnosis are originating from patient negligence and healthcare systems.3 A
community program can then be set up at various levels to address the public on patient behavior
while focusing on improving diagnostics and providing access to quality treatment. Early
diagnosis is particularly relevant to cancers of the breast, cervix, colon, larynx, mouth, rectum
and skin.

17

Another effective and practical approach to early detection is screening which provides a
thorough systematic examination of healthy and asymptomatic populations. Some existing
screening techniques include prostate-specific antigen (PSA) levels, occult blood analysis, and
mammography for the detection of prostate, colon, and breast cancer, respectively.4 These
conventional methods however are not sensitive and specific enough to reveal all types of
cancer.5 Also, some of the screening techniques are expensive and not easily accessible to a lot of
people. Due to the underlying challenges, there is the need to develop technologies that are
specific and reliable to detect cancer at an early stage for effective treatment.
Cancer Treatment
There are lots of cancer treatment methods that can be administered concurrently or
consecutively. These include surgery, targeted therapy, immunotherapy, and chemotherapy.
There are basic criteria that must be considered before administering any kind of cancer
treatment to patients. These factors include the patient’s health standing, the type of cancer, and
its location.6 The treatment target is to destroy the rapidly dividing cancer cells while having a
minimal effect on healthy cells in the body.
Of all the existing approaches, chemotherapy is by far the most widely used.
Chemotherapeutic treatments employ powerful drugs which attack the cancer cells.6 Most
chemotherapeutic agents show a promising effect on cancer cells however, their overall lack of
specificity and toxicity to healthy cells make them undesirable in cancer treatment. Some of the
adverse side-effects which make chemotherapy less tolerable to cancer patients include
peripheral neuropathy, immunosuppression, anemia, and hair loss.
The chemotherapy drugs are grouped on their molecular structure and cellular action.
These drugs are categorized as; alkylating agents, antibiotics, antimetabolites, topoisomerase I
and II inhibitors, mitosis inhibitors, and platinum compounds (Figure 1). Alkylating agents such
18

as busulfan and chlorambucil form adducts with DNA and induce cellular apoptosis in the
process. Antimetabolites including gemcitabine and methotrexate work by inhibiting purine and
pyrimidine synthesis. Doxorubicin, like daunorubicin, carries out its mechanistic action by
inhibiting topoisomerase II. Even though these drugs have potency, the result of a single
treatment remains inadequate to cure cancer. Nowadays, much attention has been shifted to the
development of combination drug therapy for cancer treatment.

Figure 1. Classification of anticancer drugs.
Combination Drug Therapy
Combination drug therapy typically combines two or more therapeutic agents to treat
cancer. This amalgamation of anticancer drugs enhances efficacy compared to mono-therapy
since they can target many key pathways in a synergistic manner. This strategy has the
advantages of reducing drug resistance, suppressing tumor growth, and inducing apoptosis.7
19

Because the drugs work additively, lower therapeutic dosages of each individual drug can be
used, thereby reducing toxicity. Additionally, combination therapy could potentially reduce
systemic toxicities if one of the drugs is antagonistic in its cytotoxic effects to the other drug.8
Despite the many benefits, combination therapy still faces a major drawback in the
administration of favorable doses to achieve the desired combinatorial effects. According to
literature sources, nanoparticles can be employed as shuttles to distribute and concentrate drugs
at the required ratios in specific cancer tissues. For example, PEGylated liposomal gemcitabine
and doxorubicin nanoparticles have been used in the treatment of advanced hepatocellular
carcinoma (HCC) with relatively high efficiency and reduced side effects.9
Nanoparticles
Nanoparticles (NPs) are particles with a diameter between 1 nm to 100 nm. They offer
emerging and exciting opportunities for cancer-based therapies.10 Multi-purpose NPs integrating
diverse roles including targeting, imaging, and therapy are currently used to surmount the
limitations of conventional cancer diagnosis and therapy. The NPs have a facile surface
modification which allows for conjugation of bio-ligands for selective detection and treatment of
cancer.11 Some NPs such as metal-based NPs (CdSe/ZnS) emit under ultraviolet-visible (UV–
Vis) light, making them excellent materials in imaging applications. Figure 2 shows NPs and
their uses in biomedicine, agriculture, cosmetics and electronics. Examples of such NPs for
biomedical research include polymer-based NPs, micelles, carbon nanotubes (CNTs), carbon
dots (CDs), hydrogels and liposomes. Of these NPs, CDs have gained the most attention lately
and are in the lead as excellent NPs for cancer diagnosis and therapy.
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Figure 2. Nanoparticles and their applications.
Carbon Dots Synthesis
For over a decade, CDs have gained much attention because of their unique
characteristics such as excellent biocompatibility, facile synthesis and easy surface modification,
which makes them applicable in diverse areas of science. CDs are nanoparticles origin from
carbon with dimensions smaller than 10 nm.12 Based on their molecular interactions with light,
CDs exhibit optical properties such a photoluminescence (PL) and chemiluminescence. The
mechanism of the PL of CDs is still unknown as it is difficult to tell the exact chemical structure
of CDs as well as functional groups contributing to the PL.13 According to literature sources, the
PL of CDs could be attributed to core state, surface state, size and quantum confinement effect,
molecular fluorophores and free zigzag sites. For example, Mandal’s group proposed that the PL
of CDs is attributed to a fluorescent moiety that is embedded in the core of CDs or attached to
21

the surface via covalent bonding.14 However, Ferrante’s group proposed that the fluorescence
properties of CDs is neither linked to the core of CDs nor moieties attached to the surface but on
free fluorescent molecules.15 Liu et al. also prepared CDs with different emissions by changing
the reaction conditions.16
Ever since their discovery, diverse synthetic routes for the preparation of carbon dots
have been proposed. The methods for carbon dots synthesis are placed into two main classes
namely top-down and bottom-up techniques (Figure 3). In the top-down process, CDs are made
by the disintegration of bulk carbon into smaller fragments via laser ablation, chemical oxidation,
arc discharge, and ultrasound treatments. On the contrary, the bottom-up process deals with the
synthesis of CDs from smaller starting materials to form nanoclusters which are then condensed
into nanoparticles. This method uses techniques such as hydrothermal/solvothermal treatment,
thermal decomposition and microwave irradiation to synthesize CDs. The top-down approach
has several advantages like increased yield, high purity, and easy manipulation of sizes.
However, their major drawbacks such as long reaction time, harsh reaction conditions and
expensive materials makes these methods less preferable.17 For example, as reported by Li et al.,
the electrochemical oxidation of graphene to obtain graphene quantum dots (GQDs) shows high
product stability. However, pretreatment of the raw materials, production and purification of
GQDs take a long time.18 Furthermore, Hu et al. irradiated a carbon target to obtain CDs using
the laser ablation technique. But this process was limited by high cost, high energy consumption,
non-uniform CD sizes and complicated purification steps.19
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Figure 3. Methods for carbon dots synthesis.
The bottom-up approaches are relatively easier compared to top-down approaches. Their
facile methods make them an excellent choice for cheap, low cost, and greener synthesis.20 Table
1 shows the major synthesis route for CDs in each category as well as the advantages and
disadvantages of each.
Table 1. Modes of Carbon Dot Synthesis and their Advantages and Disadvantages.21
Top-down

Precursor(s)

approach
Arc discharge

Emission color

Advantages

Disadvantages

Small particle

Complex

size and large

composition and

oxygen content

contains

or wavelength
Carbon nanotubes

Multicolor

impurities
Laser ablation

Graphite

450-650 nm
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Simple

Low yield

Electrochemical

Carbon nanotubes

410 nm

oxidation

Easy operation

Time-

and high yield

consuming,
expensive

Bottom-up
approach
Combustion

Candle soot

Multicolor

method
Template

Without surface

Low yield

passivation
Citric acid

Multicolor

method

Simple

Difficult to

operation,

separate CDs

uniform particle

from template

size, high yield
Pyrolysis

Citric acid

Multicolor

process

Simple, high

The formation

yield,

of CDs and the

practicability,

separation of

repeatability

small molecules
of raw materials
become more
difficult

Chemical

Hair fiber

470 nm

Simple

Poor control

oxidation

operation, low

over sizes

method

cost, large-scale
preparation
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Microwave

Glycerol and

synthesis

polyethyleneimine

Multicolor

Convenient and

The particle size

rapid heating of

distribution is

carbon

not uniform and

precursors

separation and
purification are
difficult

Hydrothermal/

L-Ascorbic acid

430 nm

Simple

Not uniform,

Solvothermal

operation,

contain many

synthesis

reliable

impurities

controllability,
favorable for
mass production

Carbon Dots Applications
Being a new kind of florescent NPs with excellent biocompatibility and less bio-toxicity,
CDs exhibit outstanding potential for multimodal bio-imaging of cancer cells and tissues.22 For
example, the Ge group synthesized red fluorescent CDs from polythiophene phenyl propionic
acid. They observed that under in vivo and in vitro conditions, HeLa cells treated with CDs
exhibited fluorescence at concentrated regions inside the cytoplasm.23 Bhunia et al. prepared
water soluble blue and yellow florescent CDs from carbon soot and nitric acid which were used
for imaging HepG2 cells.24 After that, Zhu and coworkers synthesized highly fluorescent
graphene dots via the solvothermal route and used it for imaging MG-63 cells.24 Wang et al. also
reported their folic acid-based nitrogen-doped CDs for aided detection and imaging of U87
glioma cancer cells.25
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The ability of CDs to interact with metals via surface functional groups allows for their
use in chemical sensing to detect metals like Ag+, Hg2+, Cu2+, Fe3+.26 Zhou et al. reported the use
of unmodified CDs for the detection of Hg2+ and bio-thiols. They observed that addition of Hg2+
to CDs caused fluorescence quenching while incorporation of bio-thiol restored fluorescence.27
Later, Dr. Zhang and associates synthesized graphitic CDs for the selective detection of Fe3+
ions. The team identified that the carboxyl and hydroxyl groups on the CD surface interacted
with the Fe3+ ions, thus allowing CDs to function as Fe3+ fluorescence sensor.28
CDs can also be employed as shuttles for the transportation and distribution of certain
therapeutic agents to targeted cells in the body due to their tiny size, higher biocompatibility, and
facile surface functionalization. In addition to this, the intrinsic fluorescent nature of CDs allows
for the tracking of drug delivery pathways and as a result.29 For example, Kong et al. synthesized
CDs from citric acid (CA) and ethylenediamine (EDC) and conjugated doxorubicin (DOX) to
CDs via electrostatic interaction. The new CD-DOX complexes were better internalized
compared to free DOX and showed advanced antitumor capability on the breast cancer MCF-7
cell lines.30 Zheng et al. also prepared fluorescent CDs with the anticancer drug, oxaliplatin via
condensation reaction. They showed that the carbon dot-oxaliplatin (CD-Oxa) could enter into
hepatic cancer cells with increased cytotoxic activity.31
Targeted Delivery of Anticancer Drugs
The aim of targeted delivery anti-cancer drugs is to deliver therapeutic drugs to genes,
proteins, or tissue environments directly. It is also modeled toward the development of drugs that
inhibit cancer cell replication and induce intracellular autophagy or apoptosis.32 The potential of
targeted drug delivery depends on the targeted release of therapeutics predominantly at the
cancerous tissues while minimizing the effect on healthy tissues. It also utilizes specific ligands
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like antibodies, folic acid (FA), and peptides to improve drug accumulation in cancer cells. This
can be accomplished via two main routes namely passive targeting and active targeting.33
The concept of passive targeting lies in the development of a suitable drug delivery
systems (DDS) capable of evading drug elimination pathways resulting in prolonged circulation
time and selective accumulation of the drug in the target tissue. This can be made possible via
manipulation of certain characteristics such as the size of the carrier, surface charge, molecular
weight, and its hydrophobic or hydrophilic nature.34 Passive targeting operates in two main
routes, both taking advantage of the differences between cancer and healthy cells. The first route
is known as rapid vascularization and utilizes the leaky vasculature of cancer cells. Because
cancer cells are multiplying quickly, they require speedy vascularization resulting in a weakened
vascular architecture that is more penetrable to macromolecules than normal tissues.34 This
increase in cell permeability allows for chemotherapeutic drugs to easily access cancerous
tissues. This phenomenon is known as the enhanced permeability and retention effect and results
in an increased accumulation of drugs within the cancer cells. While investigating this route,
Yang et al. intravenously injected red-emissive CDs into a xenograft-tumor bearing mice. They
observed that most of the CDs entered the cancer cells via the enhanced permeability and
retention effect and were concentrated within the tissues.35 The second route is called the tumor
microenvironment and makes use of the acidic milieu of cancer cells. This aids in the design of
pH-sensitive drug conjugates that are only degraded after entering tumor cells, leading to the
release of the active drug at the target site.36 For example, Dr. Zhou and his group exploited this
route to deliver doxorubicin (DOX) to cancer cells using CD-gated mesoporous NPs (CDMSPs). They found that the DOX-CD-MSPs showed pH-responsive drug release behavior in the
acidic milieu of HeLa cells with enhanced cytotoxicity.37
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Active targeting of cancer cells with NPs has garnered more interest in nano theranostic
due to its promising potential. In active targeting, a special targeting moiety or ligand recognized
by a specific receptor is typically conjugated to the surface of the NP to aid the site-specific
delivery of a therapeutic agent.38 Targeting agents that are often conjugated to NPs for cancer
theranostic include folic acid (folate targeting), antibodies (antibody targeting), aptamers
(aptamer targeting), and carbohydrates (carbohydrate targeting). In antibody targeting, antigens
that are overexpressed on tumor surfaces are attached to NPs for directed delivery. Aptamer
targeting utilizes oligonucleotides or peptide molecules that bind to a specific target molecule.
Carbohydrate-directed targeting involves the attachment of lectins or other proteins that bind to
cell-surface carbohydrates to target tumor cells. In folate targeting, chemotherapeutic drugs are
attached to folate conjugates that bind to folate receptors expressed on cancer cells, resulting in
receptor-mediated endocytosis.38 Of all the targeting strategies, the folate receptor seems to be a
promising target for cancer theranostics.39 Using folic acid as targeting agent, Jolanta and
associates used acetylated dendrimers to deliver methotrexate to a mice bearing tumor with
overexpressed folic acid receptor. They indicated that the folic acid-conjugated NPs concentrated
methotrexate in the tumor and increased its antitumor activity with reduced toxicity.40
Folic Acid
FA is one of target agents to actively delivery anticancer drugs. It is known as
pteroylglutamate, is an essential vitamin that is required by the body for nucleotide biosynthesis,
methylation and metabolism of amino acids. FA is a water soluble B vitamin, non-immunogenic,
inexpensive and has unique stability over a wide range of temperatures and pH.41 As show in
Figure 4, FA is composed of a pterin (2-amino-4-hydroxy-pteridine) heterocyclic ring bonded by
a methylene bridge to a p-aminobenzoyl group. The p-aminobenzoyl group is sequentially
bonded via an amide linkage to either glutamic acid or poly-glutamate. Since the hydrophilic
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nature of FA prevents it from successfully crossing the plasma membrane, cells have adopted
three transport mechanisms to allow for the uptake of this essential nutrient.42 These pathways
include, 1) the reduced folate carrier, 2) the proton-coupled folate transporter, and 3) the high
affinity folate receptor. The latter uptake system is mostly exploited for targeted cancer therapy.
The folate receptor (FR) is a glycosyl phosphatidyl inositol (GPI) anchored glycoprotein (38-45
kDa). FR binds specifically folic acid with high affinity (Kd ~ 10-9) and internalized via
endocytosis.43 The expression of FR is minimal in healthy tissues such as kidneys, lungs, the
placenta and choroid plexus. However, in certain activated macrophages and malignant tissues
like cancer (ovarian, breast, pancreatic, colon, brain, cervical), FR is overexpressed.44 This
overexpression of FR on these cells types is clinically significant as it denotes areas where
symptoms of the disease are most extensive. This makes FR an ideal therapeutic target for cancer
detection and treatment.
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Figure 4. Structure of FA
The principle of FR targeting is based on a cell deceptive strategy. Here, FA is used as a
Trojan horse molecule to aid the selective delivery of therapeutic agent to FR-expressing cancer
cells. FR targeting is a form of active targeted drug therapy that combines FA with a therapeutic
agent.45 This approach greatly improves site-specific accumulation of drugs and helps reduce
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systemic toxicities that often accompany undirected therapeutic interventions. Also, the use of
FA as a targeting agent offers several advantages compared with targeting molecules like
monoclonal antibodies or peptides. The high stability of FA over wide temperatures makes it
controllable for site-specific chemical modification. Also, FA retains its ability to bind to the
folate receptor even after conjugation to a therapeutic cargo.46 Three isoforms of the FR have
been identified in humans and includes α, β and ɣ isoforms. The α-FR is highly expressed in
rapidly dividing cancer cells like breast, ovarian, pancreatic, neck, cervical and kidney cancers.
And α-FR is the most common subtype for FA transport in these cells. Several studies have
reported folate-conjugate systems in drug delivery and imaging therapy to visualize areas with
overly expressed FRs.47 These engineered systems allow for greater control over where
chemotherapeutic agents are delivered and help improve the overall therapeutic efficacy. For
example, in his recent paper, Dr. Maghsoudinia used FA conjugated CDs to deliver bevacizumab
(BEV) to Hepa1-6 cancer cells. The analysis revealed a greater uptake of FA-CD-BEV by the
Hepa1-6 cells with increased therapeutic efficacy compared to the non-targeted CD-BEV.48 After
that, Dr. Mewada and his team used highly fluorescent FA-CD to deliver the potent anticancer
drug, DOX to HeLa cells. Cellular imaging showed internalization of FA-CD with high
accumulation of DOX due to the targeting ability of FA.49
Doxorubicin
DOX is an FDA-approved chemotherapeutic drug that is largely used in cancer treatment
due to its broad-spectrum efficacy. DOX belongs to the anthracycline family of antibiotics and
possesses remarkable antitumor activity. It was originally isolated in 1969 from Streptomyces
peucetius var. caesius by mutagenic treatment of the daunorubicin-producing Streptomyces
peucetius bacterial strain.50 Nowadays, genetic engineering strategies are employed for strain
improvement to aid production of commercially significant amounts of DOX.51
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Chemically, DOX is an amphiphilic molecule which consists of a water-insoluble
aglycone component (adriamycinone: C12H18O9) and a water-soluble functional group
(daunosamine: C6H13NO3). The latter group has basic and reducing properties.52 As shown in
Figure 5, it comprises of a tetracenequinone ring structure linked to a sugar moiety by glycosidic
bond. DOX has three main ionizable groups and therefore shows three distinct pKa values. pK1
(8.15) results from the sugar moiety of the amino group. The phenolic groups at C11 and C6
contributes to pK2 (10.16) and pK3 (13.2) respectively.53
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Figure 5. Structure of DOX
DOX is a crystalline, hygroscopic, orange-red powder which is soluble in the
hydrochloride salt form and shows varying colored solutions under different pH conditions. As a
first line chemotherapeutic drug, DOX is used to treat multiple neoplastic conditions like breast
cancer, ovarian cancer, soft tissue and bone sarcomas, neuroblastoma, acute myeloblastic
leukemia, and Wilms’ tumor. DOX is largely believed to exert its mechanistic influence on
malignant cells via two main mechanisms: i) intercalation into DNA and inhibition of
macromolecular synthesis by blocking replicative enzymes (topoisomerase II) and transcription
processes; ii) oxidative damage to DNA via production of iron-mediated free radicals. This
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oxidative destruction of DOX is attributed to its quinone structure which has the ability to
participate in redox reactions as an electron acceptor and subsequently converted to a
semiquinone radical by several enzymes.54 Despite its potency, DOX like other
chemotherapeutics is indiscriminate and non-productive and as such, possesses numerous side
effects. Clinical use of the drug has been reported to induce cardiotoxicity, hyper-pigmentation
of nailbeds and dermal creases, reversible alopecia, vomiting, diarrhea, anorexia, abdominal pain
and dehydration.55 To combat these side effects, several drug delivery systems (DDS) have been
developed to improve the specificity of DOX by successfully transporting the drug to cancer
cells. In this regard, the conjugation of DOX to carbonaceous NPs have been widely reported.56
Successful conjugation can be achieved via non-covalent means which involves the physical
adsorption of DOX to CDs or carbon nanotubes (CNTs) by electrostatic or π-π stacking
interaction. Covalent modification is also feasible by conjugating the amine functional group of
DOX to the carboxyl moieties on the surface of these carriers. In a typical example, Li et al.
covalently conjugated DOX and transferrin to CDs via carbodiimide crosslinking for targeted
delivery to pediatric brain tumor cells.57 Also, Datir and coworkers complexed DOX to a multiwalled carbon nanotube hyaluronic acid conjugate via electrostatic and π-π stacking
interactions.58 In recent times, the covalent and non-conjugation of other anticancer drugs with
various NPs have become common practice with special focus on gemcitabine, paclitaxel,
epirubicin and methotrexate.59-62 The next section discusses gemcitabine and its possible
conjugation to NPs.
Gemcitabine
Gemcitabine (GEM) also known as Gemzar, is another antimetabolite drug. Like DOX,
GEM is highly versatile and is prescribed to patients suffering from lung, ovarian, pancreatic,
cervical, bladder, breast and mesotheliomas.63 GEM is a chemical analogue to the nucleoside
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deoxycytidine and is widely known by the chemical name, 2’-deoxy-2’-difluorocytidine monohydrochloride. The structure of GEM (Figure 6) reveals that the hydrogen atoms at C2 of
deoxycytidine are di-substituted with fluorine atoms.64 As a prodrug, GEM is rapidly
metabolized into active forms following intravenous administration. The enzyme, deoxycytidine
kinase catalyzes the conversion of GEM into difluorodeoxycytidine monophosphate which in
turn is converted to two active metabolites, GEM diphosphate and GEM triphosphate.65 These
active metabolites are reported to possess anticancer activity by slowing down processes
essential for DNA production. The mechanism involves the competition of both GEM
phosphates with deoxycytidine triphosphate (dCTP) for incorporation into DNA. Once the GEM
nucleotide is inserted at the end of the DNA strand, the DNA polymerases are unable to progress
further leading to the inhibition of replicative mechanisms and cell death.66
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Figure 6. Structure of GEM
GEM is regarded as a strong sensitizer and has been reported to show synergism when
combined with other chemotherapeutic drugs.67 Alone, GEM shows poor therapeutic efficacy
due to its short half-life (8-17 min in human plasma and 9 min in murine plasma) and poor cell
membrane permeability. Because GEM is too hydrophilic, it must depend on specialized
nucleoside transporters like the human equilibrate nucleoside transporter 1 (hENT1) receptors
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found on the surface of cancer cells. This presents a major drawback to its therapeutic efficacy
since only one-third of pancreatic cancers express such a transporter.68 Also, since GEM was
intended to target rapidly dividing cells, its action is highly non-specific as it attacks both cancer
cells and rapidly dividing healthy cells like hair follicles, skin cells, intestinal and stomach lining
cells. This leads to numerous side effects such as diarrhea, vomiting, nausea, black tarry stools,
cloudy urine, joint pain, fever and blurry vision. In order to overcome these challenges, GEM has
been delivered using nanoparticle systems including polymeric, liposomes, micelles, and
mesoporous silica nanoparticles.68 GEM can be conjugated to CDs or CNTs via electrostatic and
π-π stacking interactions. Also, the amine functional moiety of GEM is usually used as a handle
for covalent conjugation of GEM to NPs with carboxyl functional groups on their surface.69
Samini et al. demonstrated successful attachment of GEM to quinic acid-based CDs via
electrostatic and π-π stacking interactions.70 Again, Ravendra and Co. covalently attached GEM
to FA functionalized multi-walled CNTs for effective targeting to cancer cells.71
Research Target
The target of this research is to engineer excellent bi-functionalized CDs-NPs as cancer
theranostic. Here, the CD (imaging agent) construct was conjugated to the targeting agent, FA,
and two anticancer drugs, DOX and GEM via covalent or non-covalent means as shown in
Figure 7 below. Based on earlier reports from Dr. Mei’s research group, it was known that the
hydrothermal reaction was the preferred route for CD synthesis with equal ratios of citric acid
and ethylenediamine.72 The CDs obtained in this ratio were easy to purify and showed consistent
drug loading profiles. Also, the previous work showed successful synthesis, conjugation, and
characterization of CDs and all CD intermediates. Functional groups such as carboxyl, amine
and hydroxyl groups were found to be present on the CDs surface and allowed for efficient
conjugation with drugs. TEM analysis showed that the synthesized CDs and intermediates had
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sizes ranging from 2 – 5 nm. However, the data on the drug load efficiency (DLE), drug release
profiles and cytotoxicity of both covalent and non-covalent CD complexes were fairly good. The
non-covalent series had very low drug loading content (DLC) compared to covalent. Therefore,
the current study aims to improve the previous data by modifying the ratios of drug to NPs and
investigating the DLE, drug release profiles and cytotoxicity. Also, at the time of this writing, the
data on non-covalent GEM-CDs and FA-CDs-GEM, including their characterization and drugrelease profiles, were lacking. Thus, investigating the non-covalent synthesis and
characterization of GEM NPs became an aim. The main objectives are outlined as follows.
Aim 1. To synthesize non-covalent FA-CDs-Dox with high concentration (HC) of DOX
and analyze the drug loading profiles.
a. To modify the concentrations and ratio of FA-CDs to DOX followed by
assessment of the %DLC and %DLE.
b.

To characterize the engineered complex using Fourier-transform infrared
spectroscopy (FTIR), fluorescence (FL) and UV–Vis spectroscopy to
confirm the successful conjugation of Dox using its unique absorption peaks.

c. To investigate the in vitro drug release.
d.

To further characterize the prepared NPs using dynamic light scattering
(DLS) and transmission electron microscopy (TEM). (Done by Dr. Guoliang
Liu, Department of Chemistry, Virginia Tech, Blacksburg, Virginia)

e.

To test the cytotoxicity of the NPs on breast cancer cell lines. (Done by Dr.
Victoria Palau, Department of Pharmaceutical Sciences, Gatton College of
Pharmacy)

Aim 2. To prepare non-covalent FA-CDs-GEM with higher GEM concentration
a. GEM will be conjugated non-covalently to FA-CDs using the same
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concentrations and ratio as in 1a.
b. The synthesized complex will then be characterized using FTIR, FL, and UV–
Vis to confirm the successful conjugation of GEM onto FA-CDs using its
unique absorption peaks.
c. To investigate the in vitro drug release and calculate %DLC and %DLE.
d. To further characterize the prepared NPs using DLS and TEM.
e. To test the cytotoxicity of the NPs on breast cancer cell lines.
Aim 3. To prepare covalent FA-CDs-DOX with higher DOX concentration.
a. To attach DOX to FA-CDs using carbodiimide crosslinking reaction.
b. The prepared complex will be characterized using FTIR, FL, and UV–Vis to
confirm the successful conjugation of DOX to FA-CDs using its unique
absorption peaks.
c. To investigate the in vitro drug release and calculate %DLC and %DLE.
d. To further characterize the prepared NPs using DLS and TEM
e. To test the cytotoxicity of the NPs on breast cancer cell lines.
Aim 4. To prepare covalent FA-CDs-GEM with higher GEM concentration
a. To load GEM onto FA-CDs via carbodiimide crosslinking reaction.
b. To characterize the engineered FA-CDs-GEM complex using FTIR, FL, and
UV–Vis to observe for the unique absorption peaks of GEM.
c. To investigate the in vitro drug release and calculate %DLC and %DLE.
d.

To further characterize the prepared NPs using DLS and TEM.

e. To test the cytotoxicity of the NPs on breast cancer cell lines.
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Figure 7. A construct of FA-CD-DOX-GEM for cancer theranostic.72
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CHAPTER 2. EXPERIMENTAL
General Information
CA, EDA, FA, Doxorubicin hydrochloride (DOX.HCl), Gemcitabine hydrochloride
(GEM.HCl), dialysis tubing with molecular weight cut-off (MWCO) of 3,500 Da, Gibco 1X
Phosphate buffer saline (PBS) pH 7.4, N-hydroxysuccinimide (NHS), and 1-ethyl-3-(3dimethylaminopropyl) carbodiimide hydrochloride (EDC.HCl) were all purchased from Fischer
scientific, USA.
Methods
Carbon Dot Synthesis
Carbon dots were synthesized by the hydrothermal bottom-up approach as reported in
previous studies with slight modification.73 CA was used as the precursor and EDA as the coreagent, serving as the nitrogen source for the carbon dots. In a typical process, 1.051 g (5.470
mmol) of CA was mixed with 335 μL (5.014 mmol) of EDA (the molar ratio of EDA to citric
acid is 1:1.1) dissolved in 10.0 ml of deionized water. The solution was then transferred to a 30
mL of Teflon-lined autoclave reactor. After the solution was heated for 5 hours at 250 oC, a darkbrown liquid solution was obtained. This solution was subsequently transferred into a 3.5 kDa
dialysis tubing and dialyzed against 500 ml distilled water for 6 hours to remove any unreacted
citric acid and EDA. The final product was lyophilized to obtain a brown-black powdered
sample with around 35 w.t % yield.
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FA-CD Synthesis
The FA-CDs were synthesized by covalent conjugation of the free amino groups on the
CDs with the carboxylic groups of FA. In a typical procedure, 20 mg of FA was first dissolved in
8 ml of 50 mM PBS buffer (pH 7.4) to obtain a clear yellow solution. Next, 4 ml aqueous
solution of 0.0260 g EDC (0.1356 mmol) and 0.0156g NHS (0.1355 mmol) (The molar ratio of
NHS to EDC is 1:1) was added to the solution of FA. The mixture was then treated by sonication
at room temperature overnight and 2 ml CDs (22 mg/mL) was added afterward (The weight ratio
of FA to CDs is 1: 2.2). The reaction was maintained under sonication conditions for another 24
hours and a final mixture was obtained. To purify this solution, the resulting mixture was
dialyzed (using a 3.5 kDa tubing) against 500 ml distilled water for 1 day to remove the
unreacted FA or CD. The final product of FA-CDs powder (yellowish-brown) with around 31
wt. % yield was collected after lyophilization.
Synthesis of Non-covalent CD-DOX with High Concentration of Dox
In a typical procedure, 1 ml of 8 mg/mL of the CDs was first sonicated for 15 minutes in
a 25 ml beaker. To this solution, 2.00 ml of 1 mg/mL DOX and 1.00 ml of 1 X PBS (pH 7.4) was
added to obtain a final mixture of 4 ml (the weight ratio of CDs to DOX was 4:1). The mixture
was covered with aluminum foil to prevent photo-degradation of DOX and stirred at room
temperature for 24 hours. The volume of the CDs-DOX after synthesis was measured with a
syringe and recorded to be 3.7 ml (low volume due to evaporation). From this solution, 0.2 ml
was taken and diluted with 1 ml DI water for UV–Vis analysis. The rest of the solution (3.5 ml)
was then dialyzed with a 3.5 kDa dialysis tube against 500 ml D.I for 2 hours to remove any
unreacted DOX or CDs. Following this, the volume of CDs-DOX after the dialysis was
measured and recorded as 3.8 ml.

39

Synthesis of Non-covalent FA-CDs-DOX with High Concentration of Dox
This step was carried out in a similar procedure as above. In this method, 1 ml of FACDs (16 mg/mL) was sonicated for 15 minutes in a 25 ml round bottom flask, and 2 ml of 1
mg/mL DOX was added. 1 ml of PBS buffer (pH 7.4) was also added to this mixture to make a
final solution volume of 4 ml (the weight ratio of FA-CDs to DOX was 8:1). This solution was
kept stirring of 200 rpm at 25 ºC in the dark (to prevent photo-degradation of DOX) for 24 hours.
The volume of the product after the reaction was measured and recorded as 3.8 ml. From this
solution, 0.2 ml was taken and diluted with 1 ml DI water for UV–Vis analysis. The remaining
FA-CDs-DOX was dialyzed in a 3.5 kDa dialysis tube against 500 ml DI water for 2 hours. The
volume of the FA-CDs-DOX after dialysis was also measured and recorded as 3.8 ml.
Synthesis of Non-covalent CD-GEM with High Concentration of GEM
In the non-covalent synthesis of CD-GEM, 1 ml of 8 mg/mL of CDs was first sonicated
for 15 mins in a 25 ml round bottom flask. After sonication, 2.00 ml of 1 mg/mL GEM and 1.00
ml of 1 X PBS (pH 7.4) was added to the solution to obtain a final mixture of 4 ml (the weight
ratio of CDs to GEM was 4:1). The mixture was further transferred into a 20 ml beaker and
stirred at room temperature for 24 hours. The volume of the CDs-GEM after synthesis was 3.7
ml. From this solution, 0.2 ml was taken and diluted with 1 ml DI water for UV–Vis analysis.
The remaining solution (CDs-GEM) was then dialyzed with a 3.5 kDa dialysis tube against 500
ml DI for 2 hours to remove any unreacted GEM or CDs. The volume of CDs-GEM after the
dialysis was 3.6 ml.
Synthesis of Non-covalent FA-CDs-GEM with High Concentration of GEM
In this method, 1 ml of 16 mg/mL FA-CDs was sonicated for 15 minutes in a 25 ml
round bottom flask, and 2 ml of 1 mg/mL GEM was added. 1 ml of PBS buffer (pH 7.4) was also
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added to this mixture to make a final solution volume of 4 ml (the weight ratio of FA-CDs to
GEM was 8:1). This solution was then transferred into a 20 ml beaker and kept under stirring
condition of 200 rpm at 25 ºC for 24 hours. The volume of the product after the reaction was 3.6
ml. From this solution, 0.2 ml was taken and diluted with 1 ml DI water for UV–Vis analysis.
The remaining FA-CDs-GEM was dialyzed in a 3.5 kDa dialysis tube against 500 ml DI water
for two (2) hours. The volume of the FA-CDs-GEM after dialysis was 3.5 ml.
Synthesis of Covalent CD-DOX with High Concentration of DOX
In the covalent synthesis of CD-DOX, 1ml of 8 mg/mL CD solution was sonicated for 15
minutes in a 25 ml round bottom flask. Then, 0.5 ml of 17mg/mL EDC (44.3 μMol) was added
to 1 ml of CD solution in a 20 ml conical flask and stirred for 30 minutes. After this time, 0.5 ml
of 10.2 mg/mL NHS (44.3 μMol) was also added and stirred for another 30 minutes. The molar
ratio of EDC to NHS was maintained at 1:1 in the synthesis. Next, 1.5 ml of 5 mg/mL DOX.HCl
(12.93 μMol) was added and stirred overnight in the dark to prevent the photodegradation of the
DOX.HCl (the overall molar ratio of DOX to EDC to NHS was 1:3.4:3.4). 0.5 ml of PBS buffer
(pH 7.4) was also added to obtain a final mixture of volume 4 ml. The mixture was then kept
under stirring (in the dark) at room temperature for 24 hours. Next, the volume of the CDs-DOX
3.6 ml. From this, 0.2 ml was taken and diluted with 1 ml DI water for UV–Vis analysis. The
remaining solution (CDs-DOX) was then dialyzed with a 1kDa dialysis tube against 500 ml DI
for 24 hours to remove any unreacted DOX or CDs. The volume of CDs-DOX after the dialysis
was 3.5 ml.
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Synthesis of Covalent FA-CDs-DOX with High Concentration of DOX
In this procedure, 1 ml of 16 mg/mL FA-CDs solution was sonicated for 15 minutes in a
25 ml round bottom flask. Next, 0.5 ml of 17 mg/mL EDC (44.3 μMol) was added to 1 ml of the
prepared FA-CD solution in a 20 ml conical flask and stirred for 30 minutes. And then, 0.5 ml of
10.2 mg/mL NHS (44.3 μMol)) was added and stirred for another 30 minutes. The molar ratio of
EDC to NHS was maintained at 1:1 in the synthesis. Next, 1.5 ml of 5 mg/mL DOX.HCl (12.93
μMol) was added and stirred overnight in the dark to prevent the photodegradation of the
DOX.HCl (the overall molar ratio of DOX to EDC to NHS was 1:3.4:3.4). 0.5 ml of PBS buffer
(pH 7.4) was also added to obtain a final mixture of volume 4 ml. The mixture was then kept
under stirring (in the dark) at room temperature for 24 hours. The volume of the FA-CDs-DOX
after synthesis was 3.7 ml. From this solution, 0.2 ml was taken and diluted with 1 ml DI water
for UV–Vis analysis. The remaining solution (FA-CDs-DOX) was then dialyzed with a 3.5 kDa
dialysis tube against 500 ml DI water for 24 hours to remove any unreacted DOX or FA-CDs.
The volume of FA-CDs-DOX after dialysis was 3.6 ml.
Synthesis of Covalent CD-GEM with High Concentration of GEM
In the covalent synthesis of CD-GEM, 1 ml of 8 mg/mL CD solution was sonicated for
15 minutes in a 25 ml round bottom flask. Then, 0.5 ml of 17 mg/mL EDC (44.3 μMol) was
added to 1 ml of CD solution in a 20 ml conical flask and stirred for 30 minutes. Following that,
0.5 ml of 10.2 mg/mL NHS (44.3 μMol) was added and stirred for another 30 minutes. The
molar ratio of the EDC to NHS was maintained at 1:1 in the synthesis. Next, 1.5 ml of 5 mg/mL
GEM.HCl (25 μMol) and 0.5 ml of PBS buffer (pH 7.4) were added to obtain a final mixture of
volume 4 ml (the overall molar ratio of GEM to EDC to NHS was 1:1.7:1.7). The mixture was
then kept under stirring at room temperature for 24 hours. The volume of the CDs-GEM after
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synthesis was 3.5 ml. From this, 0.2ml was taken and diluted with 1 ml DI water for UVanalysis. The remaining solution was then dialyzed with a 3.5 kDa dialysis tube against 500 ml
DI for 48 hours (with water changing every 24 hours) to remove any unreacted GEM or CDs.
The volume of CDs-GEM after dialysis was 3.4 ml.
Synthesis of Covalent FA-CDs-GEM with High Concentration of GEM
In this procedure, 1 ml of 16 mg/mL FA-CDs solution was sonicated for 15 minutes in a
25 ml round bottom flask. Then, 0.5 ml of 17mg/mL EDC (44.3 μMol) was added to 1 ml of the
prepared FA-CD solution in a 20 ml conical flask and stirred for 30 minutes. From then on, 0.5
ml of 10.2 mg/mL NHS (44.3 μMol) was also added and stirred for another 30 minutes. The
molar ratio of the EDC to NHS was maintained at 1:1 in the synthesis. Next, 1.5 ml of 5 mg/mL
GEM.HCl (25 μMol) and 0.5 ml of PBS buffer (pH 7.4) were added to obtain a final mixture of
volume 4 ml (the overall molar ratio of GEM to EDC to NHS was 1:1.7:1.7). The mixture was
then kept under stirring at room temperature for 24 hours. The volume of the FA-CDs-GEM after
synthesis was 3.6 ml. From this, 0.2ml was taken and diluted with 1 ml DI water for UVanalysis. The remaining solution (FA-CDs-GEM) was then dialyzed with a 3.5 kDa dialysis tube
against 500 ml DI for 48 hours (with water changing every 24 hours) to remove any unreacted
GEM or FA-CDs. The volume of CDs-GEM after the dialysis was 3.5 ml.
Preparation of Standard Calibration Curve
Different concentrations of DOX (0.001, 0.005, 0.01, 0.025, 0.05, 0.075 mg/mL) and
GEM (0.001, 0.002, 0.003, 0.01, 0.02, 0.03 mg/mL) were prepared using serial dilution and the
absorbance of the samples were taken separately at 485 nm and 269 nm respectively. A standard
calibration curve was finally obtained by plotting the absorbance against the different
concentrations of DOX and GEM.
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Characterization
The UV–Vis absorption spectra of the CDs and drug complexes were studied using
PharmaSpec UV-1700 PerkinElmer ultraviolet-visible (UV–Vis) spectrophotometer in a 1 cm
quartz cuvette. A 0.01 mg/mL concentration of the samples were prepared in distilled water and
scanned in the 200 – 900 nm wavelength range to capture all peaks present in the samples.
The fluorescence spectrum was measured by the FluoroMax-3 spectrophotometer with a
photomultiplier tube for detection, excitation and emission monochromators and a Xenon arc
lamp as excitation source. The fluorescence measurement was taken using the same samples in
the 1 cm quartz cuvette from UV–Vis analysis. All the samples were excited at different
wavelengths from 300 – 400 nm at the same integration time (0.1 seconds) with a bandwidth of
10 nm for both excitation and emission. The emission was collected in the 200 – 900 nm
wavelength range. The data was not corrected for differences in excitation intensity at the
different wavelengths in all measurements.
The powdered CD sample and the CD-drug complexes were analyzed using a Shimadzu IR
Prestige FTIR with attenuated total reflectance (ATR) accessory to determine the functional
groups and bonds present in the samples. The sample was scanned and the IR spectra was
collected in the 4000 – 450 cm-1 range.
Agarose Gel Electrophoresis of Non-covalent CDs-DOX/FA-CDs-DOX-HC
The electrostatic binding of DOX to CDs/FA-CDs under neutral conditions was
confirmed by agarose gel electrophoresis. First, 1% (w/v) agarose gel was prepared by dissolving
0.5g agarose in 50 ml 1x tris-acetate-EDTA (TAE) buffer and casted in a tray to form the gel
matrix. In the process, 30 μl of DOX, CDs/FA-CDs, and non-covalent FA-CDs-Dox solutions
(in PBS buffer, pH 7.4) were mixed separately with 20 μl of glycerol and allowed to sit for 2
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minutes. After that, 30 μl of each mixture was loaded separately into 1% (w/v) agarose gel wells
in 1x TAE buffer and run at 100 V cm-1 for 20 minutes. Glycerol was used in the loading process
to increase the density of the samples to enable them to sink into the well. No loading dye was
added since the CDs/FA-CDs NPs are self-fluorescent and can be viewed under a hand-held UVlamp. The electrophoretic mobility of the samples was dependent on their mass/charge ratio, the
ionic strength of the buffer, and the voltage used.57, 74
Agarose Gel Electrophoresis of Non-covalent CDs-GEM/FA-CDs-GEM-HC
The agarose gel electrophoresis of non-covalent CDs/GEM/FA-CDs-GEM-HC was carried
out in a similar process as above. Briefly, 30 μl of GEM, CDs/FA-CDs and non-covalent FA-CDsGEM solutions (in PBS buffer, pH 7.4) were mixed separately with 20 μl of glycerol and allowed
to sit for 2 minutes. Next, 30 μl of each mixture was loaded separately into 1% (w/v) agarose gel
wells in 1x TAE buffer and run at 100 V cm-1 for 20 minutes. After running the gel, the bands
were visualized under a 365 nm UV lamp.
Drug Load Content and Drug Load Efficiency
The DLE and DLC were assessed by UV–Vis spectrophotometry and calculated
according to a standard calibration curve. In a general procedure, 0.2 ml of each nanoparticle
(NP) complex solution was taken after synthesis and diluted to 1 ml using distilled water for
UV–Vis analysis. The maximum absorption peaks of free DOX and GEM at 485 nm and 269 nm
respectively were measured spectrophotometrically. The concentrations of free DOX and GEM
were determined from their respective standard calibration curves using the linear equation. The
amount of drug conjugated to CDs was subsequently calculated from the difference between the
amounts of free drug and the initial amount of drug used. Finally, the DLE and DLC were
calculated.
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The %DLE is given by the equation:
𝐴𝐴drug −𝐴𝐴𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓

The %DLC is given by the equation:

𝐴𝐴drug

𝐴𝐴drug −𝐴𝐴𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓
𝐴𝐴c

𝑥𝑥 100%

(1)

𝑥𝑥 100%

(2)

Where Adrug denotes the initial amount of drug used (DOX or GEM), Afree is the amount of free
drug and Ac is the initial amount of NP (CD or FA-CD) used.
Drug release kinetics
pH-dependent Drug Release of NPs
In order to investigate the drug release properties of NPs in vitro, 2 ml of the resultant
NPs solutions (after dialysis) was measured and transferred into a 3.5 kDa dialysis tubing. The
solution in the bag was dialyzed against 100 ml PBS buffer at different pH of 5.0 and 7.4. The
release systems were kept under stirring in the dark for 3 days with a speed of 200 rpm/min. In
some timed intervals (1 hr, 2 hrs, 3 hrs, 18 hrs, 22 hrs, 46 hrs, 72 hrs), 2 ml of the release media
was taken and replaced with equal volumes of fresh PBS buffer.
% Cumulative Drug Release of NPs
The amount of drug released from both DOX and GEM complexes was calculated using
the equation: Amount of Drug = Concentration x Volume x Dilution factor. Finally, the
percentage cumulative drug release (%CDR) was calculated.
The %CDR is given by the equation:
Amount of Drug

Theoretical amount of drug
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𝑥𝑥 100%

(3)

Cytotoxicity Studies
Cytotoxicity studies were conducted by Dr. Victoria Palau and Dr. Zachary F. Walls,
Department of Pharmaceutical Sciences, Gatton College of Pharmacy. The synthesized noncovalent CDs-DOX-HC and FA-CDs-DOX-HC NPs were analyzed to ascertain their efficacy on
triple-negative breast cancer cell lines. First, the MDA-MB-468 and MDA-MB-231 breast
cancer cell lines were plated in 48-well plates at a concentration of 200,000 cells/mL and grown
in Leibovitz’s medium supplemented with 15% PBS and 1% penicillin/streptomycin. They were
dosed when approximately 75% of confluence cells were treated with either CDs-DOX-HC or
FA-CDs-DOX-HC with varying DOX concentrations (0.0333−0.0001 mg/mL) diluted in serumfree media. The medium was changed after 48 hours of treatment and 5 mg/mL of 3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, MTT (Sigma-Aldrich), was added. Four
hours later, the formazan crystals were dissolved in isopropanol 0.1 N HCl, and absorbance was
measured using a SpectraMax Plus (Molecular Devices) absorbance plate reader at 570 nm.75
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CHAPTER 3. RESULTS AND DISCUSSION
Carbon Dot Synthesis
In this studies, highly luminescent CDs were synthesized by the hydrothermal pyrolysis
of CA and EDA in an autoclave reactor. This bottom-up synthetic approach does not require any
complicated steps or instruments thus, simple to perform, low cost and environmentally
friendly.76 Also, CA and EDA are accessible and inexpensive precursors, and were chosen to
provide the functional groups, -COOH, -NH2 and –OH on the CDs surface needed for efficient
conjugation of ligands. In the synthesis of CDs, CA serves as the carbon source and provides –
COOH groups. EDA acts as a surface passivating agent to enhance fluorescence and introduce –
NH2 groups. During the process, the molar ratio of CA to EDA was kept at 1:1.1 based on
previous reports by Dada.72 The CDs obtained in this ratio were stable, easy to purify and had
excellent drug loading profiles. Generally, the formation of CDs via hydrothermal pyrolysis is
believed to occur through condensation and polymerization/carbonization steps.77 As shown in
Scheme 1, heating the reaction mixture results in a condensation reaction between the carboxyl
and amine group of CA and EDA respectively. This leads to the formation of intermediates
which undergo further polymerization and carbonization until CDs are formed. The obtained CD
solution had a characteristic brown-black appearance which agreed with previous work.78 The
crude product was then dialyzed against distilled water to remove any unreacted CA or EDA and
to maintain size consistency (between 3 – 5 nm) of CDs. The purified product was further
lyophilized to obtain a brown-black powdered sample with a yield of around 35 wt. %. This low
yield could be due to the loss of some CDs during dialysis. Finally, the solid CDs were stored
(protected from light with aluminum foil wrapping) under refrigerating conditions at 5 oC to
maintain the photoluminescence stability and for further characterization.79
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Scheme 1: Hydrothermal synthesis of CDs (not drawn to scale). For simplicity, only one – NH2
and –COOH group is shown to represent the predominant functional groups on CD surface.
FA-CDs Synthesis
The synthesis of FA-CDs followed the traditional EDC/NHS bio-conjugation approach.80
In this strategy, carbodiimide crosslinking allows for the conjugation of the targeting ligand, FA
to CDs. EDC and NHS are considered as zero-length carboxyl to amine cross linkers since they
are structurally not incorporated in the final bond between the conjugated molecules.81 During
the synthesis, EDC was used to activate the carboxyl groups on the surface of FA to form an
active O-acylisourea intermediate. This intermediate is characteristically unstable under weakly
basic pH (7.4) in PBS and can undergo hydrolysis to regenerate carboxyls and an N49

unsubstituted urea. To prevent this dissociation, the O-acylisourea was reacted with NHS to form
a more stable reactive intermediate. According to literature, the reaction chemistry is compatible
in PBS under neutral conditions, albeit with lower EDC activation efficiency.67 Thus, to improve
the efficiency, the concentration of EDC was increased (molar ratio of FA to EDC is 1:2.99).
The active and more stable NHS ester intermediate is easily displaced by the primary amine
groups on the CDs via nucleophilic attack. This coupling reaction allowed for the formation of a
non-cleavable amide bond (linker 1) as shown in Scheme 2.

50

O

Folic acid

OH

O
OH
N
H

O
N

O
N
H

HN

NH2

N

Stir, 30
minutes

N

O

EDC
[ ] = R group

N

R

HN

O

N
H

Unstable O-acylisourea intermediate

Stir, 30
minutes

NHS

O
S

O

O

O

O

Amine reactive NHS ester

N
O

R

OH

+

COOH

H 2N

Carbon Dot
Stir,
overnight
R
HN
O

COOH

FA-CD Complex

Linker 1

Scheme 2: Synthesis of FA-CDs (not drawn to scale). For simplicity, only one –NH2 group of
CD is shown to react with the –COOH group of FA resulting in the formation of amide bond.
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After synthesis, the resulting FA-CDs solution was purified using dialysis to remove any
unreacted intermediates, CDs and FA. After purification, the product was lyophilized to obtain a
yellowish-brown FA-CDs powder with an approximate weight yield of 31 wt. %. The solid
product was finally stored at 5 oC to retain the fluorescence and for further characterization.
Synthesis of Non-covalent CDs-DOX/CDs-GEM NPs with High DOX/GEM Concentration
The non-covalent synthesis of CDs-DOX and CDs-GEM NPs was achieved via
electrostatic interaction between CDs and DOX or GEM. To synthesize CDs-DOX, both CDs
and DOX were initially mixed in PBS buffer at pH 7.4 under stirring conditions. According to
the literature, the weak basic nature of DOX allows for easy hydronation under neutral pH to
form cationic (+) DOX while the carboxyl group of CDs is deprotonated to produce negatively
charged (–) CDs.74, 82, 83 As a result, (+) DOX was loaded electrostatically onto (–) CDs to
produce CDs-DOX NPs. It is also possible that DOX could be attached to CDs via hydrogen
bonding due to the high hydrophilicity of CDs resulting from –COOH and –OH groups.83
Similarly, CDs-GEM NPs were produced via electrostatic and π– π stacking interactions between
CDs and GEM. Like DOX, GEM is also basic and its –NH2 group can be hydronated under
neutral conditions to produce cationic GEM which allows for electrostatic conjugation to CDs.70,
84

After synthesis, the amount of bound drug was determined spectrophotometrically before

dialysis to ascertain the % DLC and % DLE. For CDs-DOX NPs, the quantity of DOX,
measured at λmax 485 nm, was determined from the standard DOX calibration curve. For CDsGEM NPs, the amount of GEM was measured at λmax 269 nm with reference to the standard
GEM calibration curve. The resultant solutions were dialyzed to remove unbound DOX or GEM.
The purified CDs-DOX and CD-GEM NPs were finally lyophilized to obtain powdered samples.
The CDs-DOX NPs had a characteristic reddish-black appearance (approximately 24 w.t %)
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while the CDs-GEM NPs had a light brown color (approximately 26 w.t %). These solid samples
were stored at 5 oC for further characterization.
Synthesis of Non-covalent FA-CDs-DOX/FA-CDs-GEM NPs with High DOX/GEM
Concentration
The non-covalent synthesis of FA-CDs-DOX-HC and FA-CDs-GEM-HC NPs was also
accomplished via electrostatic interactions. In the process of preparing FA-CDs-DOX-HC, FACDs were first mixed with DOX in PBS buffer at pH 7.4. This condition was necessary to
facilitate the attachment of DOX to FA-CDs via hydronation of DOX into cationic (+) DOX and
deprotonation of FA-CDs to form negatively charged (–) FA-CDs. This mechanism allowed for
(+) DOX to be loaded electrostatically onto (–) FA-CDs thus forming FA-CDs-DOX-HC NPs.
Again, the excellent hydrophilicity of FA-CDs due to the presence of –COOH and –OH on the
surface, facilitated the conjugation of DOX to FA-CDs via hydrogen bonding. For FA-CDsGEM-HC, the formation of cationic GEM via hydronation under neutral conditions, facilitated
its conjugation to the negatively charged FA-CDs via electrostatic interaction.85-88 The quantity
of the bound DOX or GEM was determined by spectrophotometry before dialysis to ascertain the
% DLC and % DLE. For FA-CDs-DOX-HC NPs, the amount of DOX measured at λmax 485 nm,
was determined from the standard DOX calibration curve. For FA-CDs-GEM-HC NPs, the
amount of GEM was measured at λmax 269 nm with reference to the standard GEM calibration
curve. The remaining solutions were purified using dialysis to get rid of unreacted DOX, GEM
or FA-CDs. Afterwards, the purified products were lyophilized to obtain powdered samples. The
FA-CD-DOX-HC NPs had a characteristic reddish-yellow appearance (with around 27 % w.t)
while FA-CDs-GEM-HC NPs were yellowish-brown in appearance (approximately 29 w.t %).

53

Synthesis of Loading High Concentration of Drug onto Covalent CDs-DOX and CDs-GEM NPs
The covalent synthesis of CDs-DOX-HC and CDs-GEM-HC NPs was accomplished
through the formation of carbodiimide crosslinking between CDs and DOX or GEM. This
reaction followed the traditional EDC/NHS coupling reaction. During the synthesis, the carboxyl
moieties on the CD surface were first activated by EDC to form an actively unstable intermediate
known as O-acylisourea. The reaction was conducted in PBS buffer at pH 7.4 to ensure the
stability of the reactants and also facilitate the reaction. Also, since neutral conditions lower the
activation efficiency of EDC, the weight ratio of CD to EDC (1:2.1) was increased to
compensate for the reduced efficiency. To prevent the hydrolysis of the unstable intermediate,
NHS was added to form the more stable NHS ester intermediate which allows for an efficient
conjugation to primary amines. In the process, the NHS was displaced by the –NH2 group of
DOX or GEM via nucleophilic attack to form a non-cleavable amide bond (linker 1) thus
producing CDs-DOX-HC and CDs-GEM-HC NPs as shown in Scheme 3. After this, the amount
of bound DOX or GEM was determined by spectrophotometry to assess the % DLC and % DLE.
The amount of DOX in FA-CDs-DOX-HC NPs was measured at λmax 485 nm and calculated
using the standard DOX calibration curve. For CDs-GEM NPs, the amount of GEM was
measured at λmax 269 nm with reference to the standard GEM calibration curve. The remaining
solutions were finally purified using dialysis followed by lyophilization to obtain the powdered
samples. The CDs-DOX-HC NPs had an approximate 29 w.t % while the CDs-GEM-HC NPs
was around 30 w.t %. These samples were stored for further characterization.
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formation of amide bond.
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Synthesis of Loading High of Drug onto Covalent FA-CDs-DOX and FA-CDs-GEM NPs
The covalent synthesis of FA-CDs-DOX-HC and FA-CDs-GEM-HC NPs was completed
by EDC/NHS coupling reaction. In the reaction process, EDC activated the carboxyl groups on
the FA-CDs surface generating the unstable O-acylisourea intermediate. This intermediate was
further reacted with NHS to form the more stable NHS ester intermediate and prevent
dissociation back into carboxyl. The NHS ester facilitates efficient conjugation making it easier
for DOX or GEM to be attached to the activated FA-CDs. In this step, the –NH2 group of DOX
or GEM displaces the NHS via nucleophilic attack resulting in the formation of a non-cleavable
amide bond (linker 2) as shown in Scheme 4 below. The quantity of bound DOX or GEM was
determined spectrophotometrically at λmax 485 nm and λmax 269 nm respectively with reference
to the standard DOX or GEM calibration curve. The resultant solutions were purified using
dialysis followed by lyophilization to obtain the pure powdered products. A yield of
approximately 30 w.t % was obtained for covalent FA-CDs-DOX-HC while that of FA-CDsGEM-HC was around 33 w.t %. These samples were stored for further characterization.
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UV–Vis Analysis of Nanoparticles
The high concentration (HC) drug NPs prepared in this study were compared to the data
obtained for the low concentration (LC) drug NPs previously done by Godwin.78
UV–Vis Spectroscopy of Non-covalent CDs-DOX-HC and FA-CDs-DOX-HC
The UV–Vis spectra of non-covalent CDs-DOX-HC and FA-CDs-DOX-HC displayed
the characteristic absorption peaks of CDs, DOX and FA. According to literature, DOX and FA
have unique absorption peaks at 283 nm and 485 nm respectively. The FA-CD-DOX-HC spectra
showed typical peaks at 278 nm, 343 nm and 497 nm as shown in the green trace in Figure 8. By
comparison, it was noticed that there has been a blue-shift from 283 nm (unique absorption peak
of FA) to 278 nm. Again, there was a slight increase in wavelength from 343 nm (typical peak of
CDs) to 344 nm in FA-CD-DOX-HC. Moreover, a red-shift was observed from 485 nm (peak
characteristic of DOX) to 497 nm. These shifts could be explained by the differences in energy
levels resulting from the various surface states formed by interactions between FA-CDs and
DOX as well as functional groups present on the FA-CDs-DOX-HC surface. By comparing noncovalent CDs-DOX-HC (black trace, Figure 8) to FA-CDs-DOX-HC, it was observed that the
typical peak of FA at 283 nm did not show up in CDs-DOX-HC indicating the absence of FA.
However, a slight blue-shift from 342 nm (peak characteristic of CD) to 340 nm was seen. A
noticeable blue-shift from 485 nm, which is the characteristic absorption peak of DOX, to 459
nm was also observed. This blue shift phenomenon could be explained by electron transition
between the conduction band of the carbon core of CDs and the valence band of the protonated
amine group. The loss of the unpaired electrons on nitrogen upon protonation reduces the
electron density in CDs causing the absorption peak to be blue shifted. The UV–Vis spectra of
the complexes confirmed the successful attachment of DOX to FA-CDs.
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Figure 8. UV–Vis spectra of non-covalent CDs-DOX-HC and FA-CDs-DOX-HC obtained at
0.01 mg/mL concentration.
Comparison of UV–Vis Spectra of Covalent CDs-DOX-LC and CDs-DOX-HC
The covalent CDs-DOX-LC78 (yellow trace, Figure 9) and CDs-DOX-HC (brown trace,
Figure 9) both showed similar peak characteristics of CDs and DOX. CD-DOX-HC displayed
two unique peaks at 340 nm and 467 nm while in CDs-DOX-LC, two peaks were seen at 342 nm
and 479 nm. These peaks appear to be blue-shifted from the original peaks of CDs and DOX at
344 nm and 489 nm respectively. This blue shifted phenomena in both complexes can be
explained by the n – π* electronic transition in the conjugates due to amide bond formation. The
blue shift also indicates a strong interaction between DOX and CDs. Comparatively, the peak of
DOX in CD-DOX-HC appears to be highly blue shifted (from 489 to 467 nm) compared to CDs59

DOX-LC (from 489 nm to 473 nm) as shown in the expanded region on the graph. This region
also indicates higher DOX concentration in CD-DOX-HC compared with CDs-DOX-LC. The
distinct peak of CDs at 195 nm appears faintly in both spectra after conjugation of DOX to CDs.
Overall, the peak shifts and the slight changes in the UV spectra of both CD-DOX-LC and CDDOX-HC confirms the successful attachment of DOX to CDs.
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Figure 9. UV–Vis spectra of CDs, DOX, covalent CDs-DOX-LC and CDs-DOX-HC obtained at
0.01 mg/mL concentration.
Comparison of UV–Vis Spectra of Covalent FA-CDs-DOX-LC and FA-CDs-DOX-HC
The UV–Vis spectra of covalent FA-CDs-DOX-LC and FA-CDs-DOX-HC reveals
typical absorption peaks of CDs, FA and DOX. FA-CDs-DOX-HC (blue trace, Figure 10)
showed four unique peaks at 199 nm, 274 nm, 337 nm and 458 nm. The absorption peak at 199
nm is slightly red shifted from the original peak of CDs at 195 nm. This may be the result of the
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difference in energy levels of various functional groups and bonds present on the FA-CDs-DOXHC surface. In addition, the distinct peaks of FA, DOX and CDs at 283 nm, 489 nm and 344 nm
respectively all appear to be blue shifted to 274 nm, 337 nm and 458 nm respectively. The blue
shift could be attributed to electronic transitions between the carbon core of CDs and the amide
group on the CDs surface. The amide group reduces the electron density of the carbon core by
withdrawing electrons from the conduction band which causes the absorption peak to be blue
shifted. In FA-CDs-DOX-LC (yellow trace, Figure 10), the unique peaks occurred at 341 nm,
465 nm and 250 nm. The peak at 341 nm is marginally blue shifted from 344 nm while that at
489 nm (DOX peak) is significantly blue shifted to 465 nm. The typical absorption peak of FA
does not clearly show up in the FA-CDs-DOX-LC complex and may be due to the low
concentration of FA present in the complex. The weak absorption peak at 250 nm may be a
combined peak of both CDs (244 nm) and FA (283 nm). However, the peak shows more
characteristics of CDs than FA since the strong intensity of CDs at 244 nm may have
overwhelmed the absorption peak of FA due to the lower concentration of FA. Also, the peak at
250 nm does not show up in the FA-CDs-DOX-HC complex but a new peak at 274 nm appears.
This peak has more FA character and may be influenced by the high FA concentration (and
therefore high absorption) which has masked the peak of CDs at 244 nm. These changes in the
UV spectra confirm the successful attachment of DOX to FA-CDs NPs.
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Figure 10. UV–Vis spectra of FA, CDs, DOX, covalent FA-CDs-DOX-LC and FA-CDs-DOXHC obtained at 0.01 mg/mL concentration.
UV–Vis Spectroscopy of Non-covalent CDs-GEM-HC and FA-CDs-GEM-HC
The UV–Vis spectra of CDs-GEM-HC and FA-CDs-GEM-HC displayed the
characteristic absorption peaks of CDs, FA and GEM. As reported in previous studies, the
prepared CDs showed three distinct peaks at 194 nm (π – π* electron transition in C = C bonds),
244 nm (n – π* electron transition in C = C bonds) and 343 nm (n – π* transition of the C – N
and C=O bond). Analysis of the FA-CDs-GEM-HC (green trace, Figure 11) spectra showed
typical peaks at 199 nm, 238 nm, 272 nm and 342 nm. By comparing to pure CDs, FA and GEM,
it was noticed that the peak at 243 nm (unique absorption peak of CD) was not clearly visible in
the FA-CDs-GEM-HC complex. This could the result of overlaps of peaks of FA and GEM
which have stronger absorption than the peak of CDs at 243 nm. Moreover, there was a slight
increase in wavelength (red-shift) from 342 nm (typical peak of CDs) to 344 nm in FA-CDGEM. Again, a red-shift was observed from 196 nm (peak characteristic of CD) to 199 nm. The
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peak at 272 nm appears to be a red-shift from 269 nm, which is the unique absorption peak of
GEM. This peak (at 272 nm) overlaps the absorption of naked FA, which has a distinct
absorption peak at 283 nm. Thus, it is much likely that the strong absorption of FA has
overwhelmed the comparatively weak absorption of GEM in the FA-CDs-GEM conjugate. In
comparing non-covalent FA-CDs-GEM-HC to CDs-GEM-HC (red trace, Figure 11), it observed
that the distinct peak of FA at 283 nm does not show up in CDs-GEM indicating the absence of
FA. However, a slight red-shift from 243 nm, which is the characteristic absorption peak of CD,
to 245 nm was observed in CDs-GEM. Furthermore, the typical absorption peak of CDs at 342
nm was blue-shifted to 338 nm in the CD-GEM complex. The UV–Vis spectra of the complexes
confirmed the likelihood of a successful conjugation of FA and GEM to CDs.
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Figure 11. UV–Vis spectra of non-covalent CDs-GEM-HC and FA-CDs-GEM-HC obtained at
0.01 mg/mL concentration.
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Comparison of UV–Vis Spectra of Covalent CDs-GEM-LC and CDs-GEM-HC
Analysis of the UV–Vis spectra of covalent CDs-GEM-LC and CDs-GEM-HC exhibited
slight differences compared to that of CDs and GEM. In CD-GEM-LC (yellow trace, Figure 12),
the distinct peaks were seen at 196 nm, 247 nm and 341 nm. The peak at 196 nm appears to be
slightly red shifted from 195 nm as shown in Figure 12. Furthermore, the peaks of CD at 244 nm
and 344 nm are red-shifted to 247 nm and blue-shifted to 342 nm respectively in CD-GEM-LC.
For CD-GEM-HC (blue trace, Figure 12), similar peak characteristics were observed, however,
these peaks appeared to be more shifted compared to CDs-GEM-LC and CDs. The peak at 195
nm was significantly red shifted to 199 nm in CDs-GEM-HC while the peaks at 244 nm and 344
nm were blue shifted to 241 nm and 341 nm respectively. The characteristic red shift phenomena
in both spectra could be attributed to π – π* electron transition due to the increased conjugation
in the CDs structure. Also, the formation of amide bond contributes to a shift in absorbance to
higher wavelength due to extended conjugation.67 The slightly higher red shifted peak (199 nm)
in CDs-GEM-HC may be due to presence of more conjugation (thus greater π – π* electron
transition) resulting from the higher GEM concentration bonded to CDs. In both spectra
however, the distinct peak of GEM at 269 nm was not clearly visible. This peak may have been
overlapped by the high intensity CD absorption bands at 244 nm resulting in the slight peak shift
observed around that region. Thus, the peaks occurring at 247 nm and 241 nm in CDs-GEM-LC
and CDs-GEM-HC may reflect characteristics of both CDs and GEM, confirming the likelihood
of a successful conjugation.
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Figure 12. UV–Vis spectra of CDs, GEM, covalent CDs-GEM-LC and CDs-GEM-HC obtained
at 0.01 mg/mL concentration.
Comparison of UV–Vis Spectra of Covalent FA-CDs-GEM-LC and FA-CDs-GEM-HC
The UV–Vis spectra of covalent FA-CDs-GEM-LC and FA-CDs-GEM-HC showed
typical peaks of CDs, GEM and FA. In covalent FA-CDs-GEM-HC (black trace, Figure 13), the
characteristic peaks were observed at 198 nm, 273 nm and 340 nm. The peak at 198 nm is redshifted from 195 nm while the peak at 341 nm is slightly blue shifted from 344 nm (distinct peak
of CDs) indicating the presence of CDs. Also, the new peak at 273 nm (n – π* transition)
displays characteristics of both GEM and FA. This peak appears to have been significantly blue
shifted from 282 nm (distinct peak of FA) and may have overwhelmed the peak of GEM at 269
nm due to its strong absorption. For covalent FA-CDs-GEM-LC (violet trace, Figure 13), the
distinct peak also occurred at 341 nm indicating a blue shift from the original peak of CDs at 344
nm. The new peak at 270 nm may be due to the overlap of peaks of FA and GEM as it appears to
be blue-shifted from 283 nm and slightly red-shifted from 269 nm. Also, the strong absorption of
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CDs at 244 nm may have overwhelmed the peak of GEM at 269 nm making it less visible. These
changes in peak characteristics may confirm the likelihood of a successful conjugation of GEM
to FA-CDs.
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Figure 13. UV–Vis spectra of CDs, GEM, covalent FA-CDs-GEM-LC and FA-CDs-GEM-HC
obtained at 0.01 mg/mL concentration.

66

Fluorescence Analysis of Nanoparticles
FL of Non-covalent CDs-GEM-HC
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Figure 14. Fluorescence spectra of non-covalent CDs-GEM-HC obtained at 0.01 mg/mL
concentration. The inset is a photograph of aqueous non-covalent CDs-GEM solution taken
under a 4-watt, 365 nm UVGL-15 compact UV lamp.
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FL of non-covalent FA-CDs-GEM-HC
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Figure 15. Fluorescence spectra of non-covalent FA-CDs-GEM-HC obtained at 0.01 mg/mL
concentration. The inset is a photograph of aqueous non-covalent FA-CDs-GEM solution taken
under a 4-watt, 365 nm UVGL-15 compact UV lamp.
The fluorescence spectra in Figures 14 and 15 above shows the excitation of non-covalent CDGEM-HC and FA-CDs-GEM-HC solutions from 300 – 390 nm with 10 nm increments. For both
complexes, the highest emission maximum was observed at 440 nm when excited at 360 nm.
Both non-covalent CDs-GEM-HC and FA-CDs-GEM-HC recorded the highest fluorescence
intensity (336594 a.u. and 148452 a.u. respectively) at 340 nm while the lowest intensity (43894
a.u. and 29032 a.u. respectively) was recorded at 300 nm. Furthermore, it could be observed
from the FL spectra that increasing the excitation wavelength from 300 – 390 nm in both
complexes caused the emission to be red-shifted thus following the excitation – dependent
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emission behavior of CDs. However, a noticeable drop in fluorescence intensity could be seen in
the FA-CDs-GEM-HC spectra compared to CDs-GEM-HC. The large decrease in intensity is
explained by the fluorescence quenching effect of FA and GEM, quantum effects, surface states
and electron-hole rearrangement.67, 74, 88 Also, the differences in intensity could be attributed to
the differences in excitation intensity. The distinct emission at 440 nm explains the characteristic
blue color of the complexes when observed under a UV lamp.
Comparison of FL of Covalent FA-CDs-DOX-LC and FA-CDs-DOX-HC
The fluorescence characteristics of covalent FA-CDs-DOX-LC78 and FA-CDs-DOX-HC
were observed at different excitation wavelengths from 320 nm to 380 nm with 10 nm
increments. Both FA-CDs-DOX complexes showed an excitation-dependent emission behavior a useful property for bio-imaging. The FL spectra of FA-CDs-DOX-LC displayed the highest
emission maximum at 440 nm when excited at 360 nm. The highest intensity (177250 a.u.) was
recorded at an excitation wavelength of 360 nm while the lowest intensity (34942 a.u.) was
recorded at 300 nm. A similar effect was seen in the FL of FA-CDs-DOX-HC. The highest
emission maximum was observed at 440 nm when excited at 360 nm. The excitation at 360 nm
recorded the highest intensity (88118 a.u.) while the lowest intensity (7050 a.u.) was observed at
300 nm. Compared to CDs, both complexes showed a significant decrease in FL intensity as
shown in Figure 16 (C). This could be the result of the attachment of DOX and FA which have
been reported to decrease fluorescence via a combination of dynamic and static quenching effect
as well as inner filter effect.89, 90 However, the intensity of FA-CDs-DOX-HC was much lower
compared to FA-CDs-DOX-LC. This could be associated with the increased concentration of FA
and DOX in the covalent FA-CDs-DOX-HC complex which makes the combined quenching
effect greater than in FA-CDs-DOX-LC. Also, quantum confinement and edge effects could
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explain the large drop in FL intensity of the covalent FA-CDs-DOX-HC complex.91 The
differences in excitation intensity could also account for the differences in fluorescence
intensities. The emission at 440 nm in both complexes explains the characteristic light to deep
blue color as seen in Figure 20 (C). These changes in both complexes confirm the successful
attachment of FA and DOX to CDs.
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Figure 16. Fluorescence spectra of covalent FA-CDs-DOX-LC (A) and FA-CDs-DOX-HC (B)
obtained at 0.01 mg/mL Concentration. (C) A photograph of the aqueous complexes taken under
a 4-watt, 365 nm UVGL-15 compact UV lamp. The fluorescence intensity decreases from left
(CDs) to right (complexes) after the covalent attachment of FA and DOX. FA-CDs-DOX-LC
shows a higher intensity than FA-CDs-DOX-HC.
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Comparison of FL of Covalent FA-CDs-GEM-LC and FA-CDs-GEM-HC
The FL of covalent FA-CDs-GEM-LC and FA-CDs-GEM-HC also exhibited an
excitation-dependent emission behavior when excitation in the wavelength range of 300 – 390
nm. For FA-CDs-GEM-LC, the highest intensity (around 9000 a.u.) was observed at 360 nm
while the lowest intensity (around 4500 a.u.) was observed at 300 nm. Also, the highest emission
intensity occurred at 440 nm when excited at 360 nm but shifted to 500 nm when excited at
300nm, 310 nm, 380 nm and 390 nm. The covalent FA-CDs-GEM-HC complex showed some
distinct differences compared to FA-CDs-GEM-LC. Firstly, the highest intensity (62464 a.u.)
was recorded at 340 nm while the lowest intensity (13354 a.u.) was seen at 300 nm. Furthermore,
the highest emission maximum occurred in the range of 430 – 435 nm when excited in the
wavelength range from 300-380 nm. However, a slight emission red shift to 450 nm came off at
an excitation of 390 nm. The differences in emission peak shifts in both complexes explains the
differences in the color observed under UV light. In FA-CDs-GEM-HC, the appearance of the
blue color is influenced by the emission blue shift to 435 nm (characteristic wavelength of blue
light) while the greenish appearance of FA-CDs-GEM-LC is influenced by the emission red shift
to 500 nm (typical wavelength of green light). As shown in Figure 17 (C), the FL intensity of
both complexes were significantly lower than CDs. This could be associated with the static and
dynamic fluorescence quenching effect of FA. Also, the attachment of GEM further suppresses
the fluorescence via photo-induced charge transfer effect.92, 93 The lower FL intensity of FACDs-GEM-HC is explained by the higher concentration of FA and GEM attached to CDs which
increases the FL quenching effect in FA-CDs-GEM-HC compared to FA-CDs-GEM-LC. These
significant changes could confirm the successful attachment of GEM and FA to CDs in both
complexes.
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Figure 17. Fluorescence spectra of covalent FA-CDs-GEM-LC (A) and FA-CDs-GEM-HC (B)
obtained at 0.01 mg/mL concentration. (C) A photograph of the aqueous complexes taken under
a 4-watt, 365 nm UVGL-15 compact UV lamp. Figure 17A is reproduced with permission from
the M.S. Thesis of Godwin Babanyinah.78
Comparison of FL of Non-covalent CDs-DOX-LC and CDs-DOX-HC
The fluorescence spectra of non-covalent CDs-DOX-LC and CDs-DOX-HC shown in
Figure 18 exhibited distinct emission peak at 440 nm when excited at 340 nm. Both CDs-DOXLC and CDs-DOX-HC had the highest fluorescence intensity (361530 a.u. and 343822 a.u.
respectively) at excitation of 340 nm and the lowest intensity at 300 nm in their respective series.
Also, both complexes showed a lower intensity compared to CDs, however, the fluorescence
intensity of CDs-DOX-LC was higher than that of CDs-DOX-HC. This outcome could be
explained by the static and dynamic fluorescence quenching effect of DOX when attached to
CDs. This effect is significantly increased in the CDs-DOX-HC complex due to the increased
concentration of DOX, thus the lower intensity compared to CD-DOX-LC. An emission red-shift
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from 440 nm to 445 nm was seen in both complexes when excited at 370 nm, 380 nm and
390 nm. This emission range (440 – 445 nm) explains the characteristic blue color of the
complexes as shown in Figure 20 (C).
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Figure 18. Fluorescence spectra of non-covalent (A) CDs-DOX-LC and (B) CDs-DOX-HC
obtained at 0.01 mg/mL concentration. (C) A photograph of the aqueous complexes taken under
a 4-watt, 365 nm UVGL-15 compact UV lamp. The fluorescence intensity decreases from left to
right as the concentration of conjugated DOX increases. Thus, intensity of CDs-DOX-LC >
CDs-DOX-HC.
Comparison of FL of non-covalent FA-CDs-DOX-LC and FA-CDs-DOX-HC
In the FL spectra of non-covalent FA-CDs-DOX-LC and FA-CDs-DOX-HC the highest
intensity (199826 a.u. and 129006 a.u. respectively) was also recorded at excitation of 340 nm
when excited in the range of 300 – 390 nm. However, there was a steady decrease in the
fluorescence intensity of FA-CDs-DOX-HC compared to FA-CDs-DOX-LC. This outcome
could be explained by the fluorescence quenching effect of FA and DOX due to the dynamic or
static interactions between FA, CDs and DOX. In both complexes, the distinct emission peak
was red-shifted from 440 nm to 445 nm when excited from 370 – 380 nm. However, at λmax 390
76

nm, this emission peak shifted significantly to 460 nm and 495 nm in FA-CDs-DOX-LC and FACDs-DOX-HC respectively. This could be explained by the large increase in energy levels
resulting from the increased functional groups on the FA-CD-DOX surface.79, 94 The
predominant and distinct emission at 440 nm explains the characteristic blue color of both
complexes.
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(B) Non-covalent FA-CDs-DOX-HC
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Figure 19. Fluorescence spectra of non-covalent (A) FA-CDs-DOX-LC and (B) FA-CDs-DOXHC obtained at 0.01 mg/mL concentration. (C) A photograph of the aqueous complexes taken
under a 4-watt, 365 nm UVGL-15 compact UV lamp. The fluorescence intensity decreases from
left to right as concentration of conjugated FA and DOX increases. Therefore, intensity of FACDs-DOX-LC > FA-CDs-DOX-HC.
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FTIR Analysis of Nanoparticles
FTIR Spectra of CDs
FTIR spectroscopy was used to determine the functional groups present on the surface of
the synthesized CDs. The FTIR spectrum for the CDs displayed four predominant peaks as
shown in Figure 20 below. The four peaks were obtained at 3228 cm-1, 1651 cm-1, 1539 cm-1 and
1435 cm-1. The peak at 3228 cm-1 indicates a strong O – H stretching vibrations in carboxylic
acid and N-H stretching vibrations in primary amine (-NH2). The peak occurring at 1651 cm-1
indicates N-H bending vibrations of amine and a strong C=O stretch in amide. Also, the peak at
1539 cm-1 indicates a strong N – O stretching while the strong peak at 1435 cm-1 represents C –
H asymmetric stretching. The occurrence of these peaks indicates the presence of – OH, –NH2,
and –COOH groups on the surface of CDs which contributes to the high water solubility of CDs.
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The above data also agrees with the work of Yuan et al.74
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Figure 20: FTIR spectrum of CDs.
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FTIR Spectra of FA-CDs
The FTIR spectrum for the FA-CDs displayed distinct peaks at 3097 cm-1 – 3317 cm-1,
1689 cm-1, 1643 cm-1, 1604 cm-1, 1570 cm-1 and 1485 cm-1 as shown in Figure 23 below. From
literature, FA displays distinct peaks at 1694 cm-1 representing C=O stretching from –COOH,
1640 cm-1 indicating C=O stretching from –CONH2, and 1607, 1570, 1485 cm-1 corresponding
to phenyl and pterin rings. The FA-CD spectra showed not only characteristic peaks of CDs
(1643 cm-1 and 1570 cm-1) themselves but also peaks at 1689 (C=O stretching), 1604 and 1485
cm-1 (phenyl and pterin rings). This indicates that FA is present. The strong and broad peak at
3097 cm-1 – 3317 cm-1 corresponds to the O-H stretching vibrations of carboxylic acid and N-H
stretching of amine. Also, the new peak occurring at 1689 cm-1 is not present in CDs. This peak
represents a strong C=O stretch of amide bond and underpins the successful conjugation of FA to
CDs.
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Figure 21: FTIR spectrum of FA-CDs.
Comparison of FTIR Spectra of Covalent CDs-DOX-LC and -HC
The IR spectra below shows the comparison of covalent CDs-DOX at low (CDs-DOXLC) and high (CDs-DOX-HC) DOX concentration relative to pure CDs. Both spectra showed the
similar distinct peaks at around the same regions of absorption. CDs-DOX-LC78 has a peak at
around 1705 cm-1, which is comparable stronger (possibly due to a lower mass effect resulting
from less attached DOX) than the peak at 1697 cm-1 for CDs-DOX-HC. However, the new and
weak absorption band at 1435 cm-1 (O-H bending of alcohol) in covalent CDs-DOX-HC did not
show up in covalent CDs-DOX-LC. This peak could be overshadowed by the peak at 1400 cm-1
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since it occurs faintly in CDs-DOX-LC. Finally, the absorption bands at around 1700 cm-1 and
1222 cm-1 which show the C=O stretch of amide and strong C-N stretch of amine respectively,
are not present in either CDs or DOX. The appearance of these new peaks signifies the
successful formation of covalent bonds and the possible conjugation of DOX to CDs.
Table 2. Unique IR Absorption Peaks of Covalent CDs-DOX-LC and -HC
Sample ID

DOX

CD
Covalent CDs-DOX-LC

Covalent CDs-DOX-HC

Unique IR Absorption Peaks (cm−1)
3394 (s), 2939 (w), 1724 (s), 1616 (s), 1581 (s), 1284 (s),
1118 (s), 1014 (s)
3228 (s), 1651 (m), 1539 (s), 1435 (s)
3317 (s), 2970 (s), 1705 (s), 1643 (s), 1562, 1227 (m), 1076 (w)
3305 (m-s), 2935 (s), 1697, 1647 (s), 1558 (m-s), 1222 (s),
1041 (m)
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Figure 22: FTIR spectrum of covalent (A) CDs-DOX-LC and (B) CDs-DOX-HC.
Comparison of FTIR Spectra of Covalent FA-CDs-DOX-LC and -HC
The IR spectra of both covalent FA-CDs-DOX-LC and FA-CDs-DOX-HC displayed
characteristic peaks CDs, DOX and FA at around the same absorption regions. In both spectra, a
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new peak can be seen arising at around 1700 cm-1 representing the C=O stretch of the amide
bond. But, the intensity of this peak is stronger in covalent FA-CDs-DOX-HC compared to FACDs-DOX-LC. This may be due to the formation of more amide bonds leading to a stronger
amide bond character in FA-CD-DOX-HC. Also, two new peaks can be seen appearing in both
spectra at around 1481 cm-1 and 1435 cm-1. The peak at 1481 cm-1 corresponds to the phenyl and
pterin rings of FA while that at 1435 cm-1 represents the O-H bending vibrations of primary
alcohol of DOX. The formation of these new peaks indicate the possibility of a successful
conjugation of FA and DOX to CDs.
Table 3. Unique IR Absorption Peaks of Covalent FA-CDs-DOX-LC and -HC
Sample ID
DOX

Unique IR Absorption Peaks (cm−1)*
3394 (s), 2939 (w), 1724 (s), 1616 (s), 1581 (s), 1284 (s),
1118 (s), 1014 (s)

CD

3228 (s), 1651 (m), 1539 (s), 1435 (s)

FA

3546 (s), 3111 (s), 2927 (s), 1693 (s), 1605 (m), 1484 (w)

Covalent FA-CDs-DOX-LC

3348 (m-s), 2970 (s), 1739, 1643 (s), 1566 (m-s), 1377 (w),
1234 (m), 1049–1087 (s)

Covalent FA-CDs-DOX-HC

3305 (m), 2935 (s), 1701 (s), 1643 (s), 1558 (s), 1481, 1392
(w), 1222 (s) 1010 (s)

*s – strong, w – weak, m – medium, m-s – medium to strong
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Figure 23: FTIR spectrum of covalent (A) FA-CDs-DOX-LC and (B) FA-CDs-DOX-HC.
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Comparison of FTIR Spectra of Non-covalent FA-CDs-DOX-LC and HC
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Figure 24. FTIR spectrum of non-covalent A) FA-CDs-DOX – LC and B) FA-CDs-DOX – HC
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Table 4. Unique IR Absorption Peaks of Non-covalent FA-CDs-DOX-LC and -HC
Sample ID
DOX

Unique IR Absorption Peaks (cm−1)*
3394 (s), 2939 (w), 1724 (s), 1616 (s), 1581 (s), 1284 (s), 1118 (s),
1014 (s)

CD

3228 (s), 1651 (m), 1539 (s), 1435 (s)

FA

3546 (s), 3111 (s), 2927 (s), 1693 (s), 1605 (m), 1484 (w)

FA-CDs-DOX LC

3093-3321 (m-s), 2978 (s), 1689 (s), 1651 (m-s), 1604 (s), 1539 (s),
1400 (m), 1135 (s)

FA-CDs-DOX HC

3078-3329 (s), 2924 (s), 1635 (s), 1612 (s), 1573 (s), 1462 (w), 1010 (s)

*s – strong, w – weak, m – medium, m-s – medium to strong
The FTIR spectra in Figure 24 shows the comparison of non-covalent FA-CDs-DOX complex at
low (A– FA-CDs-DOX - LC) and high (B – FA-CDs-DOX - HC) concentrations relative to pure
CDs, DOX and FA. Spectra A for FA-CDs-DOX – LC72 shows distinct peaks of CDs at 1651
cm-1 and 1539 cm-1 indicating strong C=O stretch in amide, N-H bending in amine and strong NO stretching respectively. Also, the unique peaks of FA showed up at 1689 cm-1 (strong C=O
stretch of amide, strong aromatic C=C stretch and bend) and 1604 cm-1 (N-H bending vibration
of –CONH group). The peak for DOX at 1581 cm-1 may have been masked by the peak of CD at
1539 cm-1 as this peak for DOX is not distinct in the FA-CDs-DOX - LC complex. It could also
be that this peak (1581 cm-1) was formed but very weakly and therefore could not show up in the
spectrum as observed. Again, the new peak arising at 1400 cm-1 (O-H bending of alcohol) in FA-
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CDs-DOX – LC does not show up in either FA or CDs but shows similarities to the peak of
DOX at 1411 cm-1 indicating the possible presence of DOX. The peaks at 3093 – 3321 cm-1
represents O-H stretching vibration in –COOH and N-H bending in –NH2.
In FA-CDs-DOX – HC, the multiple peaks showing at 1573 – 1635 cm-1 represents strong C=O
stretching and NH2 scissoring of amine. The peak at 1635 cm-1 may have overlapped with the
distinct peak of CDs at 1651 cm-1. Again, the peak at 1612 cm-1 (N-H bending vibrations) may
have overlapped with the distinct peaks of FA and DOX at 1605 cm-1 and 1616 cm-1
respectively. The FA-CD-DOX – HC complex shows varying distinct peak characteristics of
DOX at 1573 cm-1, 1010 cm-1 (strong C-O stretching in primary and secondary alcohols) and
1612 cm-1 indicating the possible attachment of DOX. However, the unique peak of FA at 1693
cm-1 does not show up in the FA-CDs-DOX – HC complex, even though the peak at 1462 cm-1
which is also unique for FA and representing the phenyl and pterin rings showed up. The peaks
showing at 3271-3329 cm-1 represents O-H stretching vibrations in –COOH and N-H bending in
–NH2. The new but weakly formed peak at 1408 cm-1 (O-H bending of alcohol) and the strong
peak at 1207 cm-1 shows similar peak characteristic to DOX at 1411 cm-1 and 1211 cm-1
respectively.
Comparing FA-CD-DOX – LC and FA-CD-DOX – HC, it could be seen that the peak for FA at
1689 cm-1 showed up in FA-CDs-DOX – LC but not in FA-CDs-DOX – HC, even though both
complexes showed the peaks for phenyl and pterin rings of FA at 1462 cm-1 (FA-CDs-DOX –
HC) and 1482 cm-1 (FA-CDs-DOX – LC). Also, the peaks of DOX at 1014 cm-1 and 1211 cm-1
does not show up in FA-CD-DOX – LC but is represent in FA-CD-DOX – HC at 1010 cm-1 and
1207 cm-1. In both complexes however, it is possible that there is non-covalent attachment of
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DOX and FA to CDs due to the presence of distinct peaks reported above. Functional groups
such as –COOH, –NH2 and –OH are possibly present in both complexes as well.
FTIR Analysis of GEM and GEM-NPs
FTIR Spectroscopy of GEM
The FTIR spectrum of GEM shows the distinct absorption peaks of pure GEM occurring
at 3402 cm-1, 3232 cm-1, 3120 cm-1, 1693 cm-1, 1651 cm-1, 1519 cm-1, 1130 cm-1 and 1087 cm-1.
The broad peak occurring within the range of 3120-3402 cm-1 corresponds to a strong O-H
stretching of alcohols and N-H stretching of primary amine. The strong peaks occurring at 1693
cm-1 represent a strong C=O stretching. The sharp peaks at 1651 cm-1 and 1519 cm-1 correspond
to the N-H bending of primary amine and C=O stretching of carbonyl. The absorption peaks at
1087 cm-1 and 1130 cm-1 represents a strong C-F stretching and C-O stretching in primary
alcohols respectively. The sharp, strong peak at 1207 cm-1 corresponds to the C-N stretching of
amine.
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% Transmittance

Wavenumber (cm−1)
Figure 25: FTIR spectrum of GEM.
Comparison of FTIR Spectra of Covalent CDs-GEM-LC and Covalent CDs-GEM-HC
The IR spectra of covalent CDs-GEM-LC and CDs-GEM-HC showed subtle differences
compared to pure CDs and GEM. For covalent CDs-GEM-LC, the predominant peaks could be
seen at 3352 cm-1 (strong O-H stretch and N-H stretch vibrations), 1697 cm-1 (C=O stretch in
amide bond), 1635 cm-1 (C=O stretch of amide and N-H bending vibrations in amine), 1554 cm-1
– 1543 cm-1 (N-H bending of amine), 1435 cm-1 (O-H bending of alcohol), 1369 cm-1 – 1396 cm1

(O-H bending of alcohol) and 1203 cm-1 – 1230 cm-1 (strong C-N stretch of amine). The peak

at 1697 cm-1 is not present in both CDs and GEM and confirms the likelihood of a successful
covalent attachment. Like CDs-GEM-LC, the IR spectra for covalent CDs-GEM-HC displayed
similar peak characteristics with the major peaks occurring at 3348 cm-1 (strong O-H stretch and
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N-H stretch vibrations), 1705 cm-1 (strong C=O of amide bond), 1635 cm-1 – 1651 cm-1 (strong
N-H bending of amine and C=O stretch of amide), 1558 cm-1 (strong N-H bending vibrations),
1481 cm-1 (strong C-O stretch and O-H stretch of alcohol), 1219 cm-1 (strong C-N stretch of
amine) and 1080 cm-1 (C-F stretch of fluoro compound). Comparatively, the absorption bands of
covalent CD-GEM-HC are stronger than covalent CDs-GEM-LC. This could be the result of
more bonds formed on the CDs surface due to the increased concentration of GEM. As shown in
Figure 26, the peak at 1701 cm-1 in covalent CDs-GEM-HC represents the similar C=O stretch
in GEM drug alone. But the peaks at 1651 and 1635 are distinctly different than the GEM and
LC GEM complex. Also, the new peak at 1481 cm-1 (strong C-O stretch and O-H stretch of
alcohol) in CD-GEM-HC is not present in CD-GEM-LC. The distinct peak at 1080 cm-1 (typical
GEM peak) which represent strong C-F stretching shows up prominently in CD-GEM-HC but
only weakly in CD-GEM-HC. This shows that more GEM could be covalently attached to CDs
in the CD-GEM-HC complex compared to CD-GEM-LC.
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Table 5. Unique IR Absorption Peaks of Covalent CDs-GEM-LC and -HC
Sample ID

GEM

Unique IR Absorption Peaks (cm−1)*

3402 (s), 3232, 3120 , 1693 (w), 1703 (s), 1651 (s),
1519 (s), 1130 (s), 1087 (s)

CD
Covalent CDs-GEM-LC

3228 (s), 1651 (m), 1539 (s), 1435 (s)
3275 -3352 (s), 2970 (s), 1697 , 1635 (s), 1554 (s),
1369 (m), 1230 (s)

Covalent CDs-GEM-HC

3348 (m-s), 2978 (s), 1705 (s), 1651, 1635 (m-s), 1558 (w),
1219 (m), 1080 (s)

*s – strong, w – weak, m – medium, m-s – medium to strong
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Figure 26: FTIR spectrum of covalent (A) CDs-GEM-LC (B) CDs-GEM-HC
Comparison of FTIR Spectra of Covalent FA-CDs-GEM-LC and Covalent FA-CDs-GEM-HC
Analysis of the IR spectra of covalent FA-CDs-GEM-LC revealed distinct peaks at 3302
cm-1 (strong N-H and O-H stretch), 1697 cm-1 (C=O stretch of amide), 1647 cm-1 (N-H bending
of amine and C=O stretch of amide), 1543 cm-1 – 1558 cm-1 (N-H bending of amine), 1396 cm-1
(O-H bending of alcohol), 1207 cm-1 (C-N stretching of amine) and 1153 cm-1 (C-O stretching of
93

tertiary alcohol). Similarly, in FA-CDs-GEM-HC the distinct peaks can be seen occurring
prominently at around the same regions even though more peaks showed up compared to FACD-GEM-LC. The new peaks appearing at 1604 cm-1 and 1481 cm-1 in FA-CDs-GEM-HC did
not show up in FA-CDs-GEM-LC. These peaks are the predominant peaks of FA and indicate
their presence in FA-CDs-GEM-HC. The peak at 1604 cm-1 corresponds to the N-H bending
vibrations of –CONH group while that at 1481 cm-1 represents the phenyl and pterin rings of FA.
Also, the new peaks at around 1700 cm-1 (strong C=O stretch) and 1200 cm-1 (strong C-N
stretching of amine) formed in both spectra indicate the successful formation of an amide bond
and confirms the covalent attachment of GEM to FA-CDs.
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Table 6. Unique IR Absorption Peaks of Covalent FA-CDs-GEM-LC and -HC
Sample ID

GEM

Unique IR Absorption Peaks (cm−1)*

3402 (s), 3232, 3120 , 1693 (w), 1703 (s), 1651 (s),
1519 (s), 1130 (s), 1087 (s)

CD

3228 (s), 1651 (m), 1539 (s), 1435 (s)

Covalent FA-CDs-GEM- 3302 (s), 2927 (s), 1697 (s), 1647 (s), 1558 (s), 1396 (m),
LC

1207 (s)

Covalent FA-CDs-GEM- 3317 (m-s), 2978 (s), 1697 (s), 1651, 1635 (m-s), 1604 (w),
HC

1546 (m), 1481 (s), 1228 (s)
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Figure 27: FTIR spectrum of covalent (A) FA-CDs-GEM-LC and (B) FA-CDs-GEM-HC.
FTIR Spectroscopy of Non-covalent CDs-GEM-HC
The FTIR spectrum for the CDs-GEM displayed distinct peaks at 3340 cm-1, 2939 cm-1,
1651 cm-1, 1553 cm-1, 1543 cm-1, 1373 cm-1 and 1049 cm-1 as shown in Figure 34 below. The
broad peak from 3340 cm-1 reveals the presence of O-H stretching (in carboxylic acid) and N-H
stretching vibrations in primary amine, and the absorption peak at 2947 cm-1 represents the
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presence of C-H stretching vibrations. The absorption peaks at 1651 cm-1 and 1553 cm-1
corresponds to N-H bending of primary amine, strong C=O stretch of amide and strong N-O
stretch. Also, the medium peak at 1373 cm-1 corresponds to the O-H bending of alcohol while the
peak at 1049 cm-1 represents a strong C-O stretching of primary alcohol. The medium sharp peak
occurring at 1203 cm-1 represents C-N stretching of amine. The weak peaks occurring at 1435 –

% Transmittance

1458 cm-1 corresponds to the O-H bending of carboxylic acid and C-H bending of methyl.

Wavenumber (cm-1)
Figure 28: FTIR spectrum of non-covalent CDs-GEM.
FTIR Spectroscopy of Non-covalent FA-CDs-GEM-HC
The IR spectrum in Figure 29 below shows absorption peaks that indicates the evidence
of conjugation of FA-CDs and GEM via electrostatic and π-π stacking interactions. The broad
peak at 3197-3425 cm-1 reveals the presence of O-H stretching vibrations in carboxylic acid and
N-H stretching of primary amine. The peaks at 1643 cm-1 (peak characteristic of CDs) and 1566
cm-1 corresponds to a strong C=O stretching in amide bond and N-H bending of primary amine.
The absorption peaks at 1600 cm-1 and 1486 cm-1 (characteristic peaks of FA) corresponds to the
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N-H bending vibrations of amide and the phenyl and pterin rings of folic acid respectively. It is
possible that the strong peak at 1643 cm-1 may have overwhelmed the new but weakly occurring
peak at 1689 cm-1 (C=O stretching of amide) which is also a characteristic peak of FA. The
peaks occurring at 1381 cm-1 and 1292 cm-1 represents strong O-H stretching of alcohol and C-N
stretching of aromatic amine respectively. The strong, broad peak at 1041 cm-1 represents strong

% Transmittance

C-O-C stretch.

Wavenumber (cm-1)
Figure 29: FTIR spectrum of non-covalent FA-CDs-GEM.
Agarose Gel Electrophoresis of Non-covalent CDs-DOX/FA-CDs-DOX Complexes
During electrophoresis, the anode is positively charged while the cathode is negatively
charged. After the process, the CDs migrated farthest to the anode while DOX did not move at
all as shown in Figure 30. This confirmed that the CDs were negatively charged and DOX was
positive. Comparing the migratory distance of CDs to the noncovalent FA-CDs-Dox complexes,
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it can be seen that the complexes traveled shorter distances. This is because the binding of DOX
and FA decreased the surface negative charge of CDs resulting in a slower travel distance.
However, the electrophoretic mobility of FA-CDs was faster and traveled farther than CDs/DOX
and FA-CDs-DOX. This is because FA-CDs have a smaller size and a greater negative surface
charge than CDs-DOX/FA-CDs-DOX and so move faster. FA-CDs-DOX traveled the slowest
because of their greater mass and smaller charge. Overall, the anodic migration and fine
separation of CDs/FA-CDs NPs confirmed that the interaction between DOX and CDs is
electrostatic.95

Figure 30. A digital photo of the agarose gel electrophoresis of CDs, DOX, FA-CDs, noncovalent CDs-DOX and FA-CDs-DOX viewed under a 4-watt, 365 nm UVGL-15 compact UV
lamp.
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Agarose Gel Electrophoresis of Non-covalent CDs-GEM/FA-CDs-GEM Complexes
A similar process as above was repeated for non-covalent CDs-GEM/FA-CDs-GEM to
confirm the electrostatic loading of GEM to CDs/FA-CDs NPs. The result showed that CDs had
the fastest electrophoretic mobility and migrated farthest to the anode, indicating that CDs is
smaller-sized and negatively charged. Comparing CDs to the GEM complexes, it could be seen
that the complexes showed slower migratory potential. But, CDs-GEM traveled faster than both
FA-CDs and FA-CDs-GEM as shown in Figure 33. This is because though the negative surface
charge of CDs-GEM might be lower than FA-CDs, the size of GEM is significantly smaller than
FA, thus making the resultant size of CDs-GEM smaller than FA-CDs. The smaller the size the
greater the migratory distance. FA-CDs-GEM travelled the least distance due to its large size and
lower surface charge. Also, GEM and Cu2+ (as positive control) did not move from their wells,
indicating that GEM is positively charged and strongly attracted to the negatively charged
cathode. These results successfully prove that the interaction between GEM and noncovalent
CDs/FA-CDs NPs is indeed electrostatic.
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Figure 31. A digital photo of the agarose gel electrophoresis of CDs, Cu2+, GEM, FA-CDs, noncovalent CDs-GEM and FA-CDs-GEM viewed under a 4-watt, 365 nm UVGL-15 compact UV
lamp.
Drug Loading Profile of Covalent and Non-covalent CDs-DOX/GEM and FA-CDs-DOX/GEM
Complexes
Currently, increasing the drug loading in NPs remains a major challenge thus, new
strategies need to be adopted.96, 97 In this study, we increased the concentration of drugs and CDs
NPs and assessed their %DLE and %DLC. As shown in table 2, the %DLE of the non-covalent
NPs was higher than their covalent counterparts. The high %DLE could be influenced by the
physical or electrostatic adsorption of DOX/GEM to CDs/FA-CDs NPs as reported in other
studies.98, 99 However, the %DLC of the covalent series was significantly higher than the non101

covalent series. The huge difference in %DLC could be associated with the quantity of drug
loaded onto CDs/FA-CDs NPs. The amount of loaded DOX/GEM in the covalent series is about
4-5 times higher than in the non-covalent series. In the covalent CD-DOX/GEM series,
increasing the concentration of the drug increased both the %DLC and %DLE in the HC series
compared with the LC series (table 7 and 8). The high %DLC could be attributed to the increased
molar concentration of the drug loaded onto the HC series which is about 2-3 times higher than
in the covalent LC series. Also, the high %DLE could be the result of the greater mass of
conjugated drugs in the HC series than in LC. A similar trend was seen in the non-covalent HC
series compared with the LC series. Also, both the LC and HC series of covalent FA-CDsDOX/GEM NPs showed a similar trend in the %DLC even though the %DLE was higher in the
HC series. The low %DLC might be due to the attachment of FA which increases the size and
reduces the surface area of CDs thereby preventing more drugs to bind to CDs.100 Overall, the
results indicate that increasing the drug to CDs NPs ratio might increase the %DLE and %DLC
and therefore could be investigated further.
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Table 7. Drug Loading Profile of Covalent and Non-covalent DOX NPs
Sample

Non-covalent

DOX

CD/FA-CD

%DLE

%DLC

mL (mg/mL)

mL (mg/mL)

1.0 (0.4)

1.0 (4.0)

83.8

3.9

2.0 (1.0)

1.0 (16.0)

94.6

10.1

0.5 (5.0)

1.0 (4.0)

71.0

50.0

1.5 (5.0)

1.0 (16.0)

93.3

29.1

0.5 (5.0)

1.0 (4.0)

53.7

60.9

1.5 (5.0)

1.0 (8.0)

86.7

43.1

2.0 (1.0)

1.0 (8.0)

94.1

18.4

(FA-CD-DOX LC)
Non-covalent
(FA-CD-DOX HC)
Covalent
(FA-CD-DOX LC)
Covalent
(FA-CD-DOX HC)
Covalent
CD-DOX-LC
Covalent
CD-DOX-HC
Non-covalent
CD-DOX-HC
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Table 8. Drug Loading Profile of Covalent and Non-covalent GEM NPs
Sample

Covalent

GEM

CD/FA-CD

%DLE

%DLC

mL (mg/mL)

mL (mg/mL)

0.5 (5.0)

1.0 (8.0)

69.6

37.8

1.5 (5.0)

1.0 (16.0)

81.4

26.4

0.5 (5.0)

1.0 (4.0)

75.1

46.9

1.5 (5.0)

1.0 (8.0)

80.5

35.1

2.0 (1.0)

1.0 (16.0)

87.3

9.0

2.0 (1.0)

1.0 (8.0)

80.1

17.6

(FA-CD-GEM LC)
Covalent
(FA-CD-GEM HC)
Covalent
(CD-GEM LC)
Covalent
(CD-GEM HC)
Non-covalent
(FA-CD-GEM HC)
Non-covalent
(CD-GEM HC)
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pH-responsive Drug Release
The concentration of drug released at any given time was quantified using UV–Vis
spectrophotometry. For CDs-GEM-HC and FA-CDs-GEM-HC, a UV–Vis measurement was
carried out on the collected released media at 269 nm and the concentration of GEM released
was quantified using the standard calibration curve of pure GEM as shown in Figure 32 below.
For CDs-DOX-HC and FA-CDs-DOX-HC, a UV–Vis measurement was carried out on the
collected released media at 485 nm and the concentration of DOX released at the various time
intervals was interpolated from the standard calibration curve of pure DOX as seen in Figure 33.
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R² = 0.9988
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Figure 32. Standard calibration curve of GEM.
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Figure 33. Standard calibration curve of DOX
Comparison of Drug Release of Non-covalent FA-CDs-DOX-LC and -HC
The free DOX released from non-covalent FA-CDs-DOX-LC78 and FA-CDs-DOX-HC
were assessed in different PBS buffer systems to study the effect of changing pH values on the
existing electrostatic interaction between DOX and FA-CDs. The buffer systems, at pH 5.0 and
7.4, were distinctively chosen to mimic the tumor microenvironment and extracellular pH of
normal tissues and blood respectively. According to the literature, DOX shows pH-dependent
solubility, whereby it is more soluble at pH 4-5 than at pH 7.4.101 By analyzing the release
kinetics of drug in vitro, it could be seen that there was an initial fast release of DOX (at pH 5.0)
within the first 22 hours in both pH systems for non-covalent FA-CD-DOX NPs. Also, the rate
of drug release at the same timed interval in both systems, was comparably higher in pH 5 than
in pH 7.4. At the end of the 72-hour drug release period, the cumulative drug release of FA-CDsDOX-HC was 8-9 times higher in acid than in neutral conditions. The FA-CDs-DOX-LC is
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around 4 times. Overall, this ratio suggests that FA-CDs-DOX-HC will have more
potential/efficiency to release more DOX drugs at cancer sites.
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(B) Non-covalent FA-CDs-DOX-HC
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Figure 34. A graph showing the pH-responsive release of DOX from non-covalent (A) FA-CDsDOX-LC and (B) FA-CDs-DOX-HC in PBS buffer at pH 5.0 and 7.4.
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Comparison of Drug Release of Covalent FA-CDs-DOX-LC and -HC
The drug release kinetics in covalent FA-CDs-DOX-LC78 and HC was slower in pH 5.0
compared to their non-covalent FA-CDs-DOX counterparts. This could be the result of the extra
stability associated with the amide bond formed in the covalent FA-CDs-DOX complexes, which
is also a much stronger bond than the electrostatic interaction in the non-covalent FA-CDs-DOX
series. Comparatively, the drug release rate in both covalent FA-CDs-DOX-LC and FA-CDsDOX-HC was faster in pH 5.0 than pH 7.4 as shown in Figure 35. Also, FA-CDs-DOX-HC
recorded a higher cumulative drug release ratio (58%) after the 72-hr drug release period than
FA-CDs-DOX-LC (44.9%). The result further indicates that the release of DOX in FA-CDsDOX is about 4 times higher in acid than in neutral media. In FA-CDs-DOX-LC, the DOX
release is only about 3 times higher.
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Figure 35. A graph showing the pH-responsive release of DOX from covalent (A) FA-CDsDOX-LC and (B) FA-CDs-DOX-HC in PBS buffer at pH 5.0 and 7.4. Figure 35 A is reproduced
with permission from the M.S. Thesis of Godwin Babanyinah.78
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Comparison of Drug Release of Covalent FA-CDs-GEM-LC and -HC
Comparing covalent FA-CDs-GEM-LC78 and HC, it could be seen that the drug release
ratio of both complexes was higher at pH 5.0 than at pH 7.4 as shown in Figure 36. However,
after the 72-hr period, the GEM release in covalent FA-CDs-GEM-HC was slightly higher (50%)
than in FA-CDs-GEM-LC (44%). This is due to the increased quantity of GEM in FA-CDsGEM-HC which causes more GEM to be released under pH 5.0. At the end of the 72-hr drug
release period, the cumulative GEM release ratio in FA-CDs-GEM-HC was about 3 times higher
in pH 5.0 than pH 7.4. For FA-CDs-GEM-LC, the GEM release was around 2 times higher. In
all, the higher GEM release under acidic conditions makes it preferable for selective targetability
to cancer cells.
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Figure 36. A graph showing the pH-responsive release of GEM from covalent (A) FA-CDsGEM-LC and (B) FA-CDs-GEM-HC in PBS buffer at pH 5.0 and 7.4.
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Drug Release of Non-covalent FA-CDs-GEM-HC
Analysis of the drug release of non-covalent FA-CDs-GEM showed that the release
kinetics at any given time was higher under acidic conditions than at neutral conditions. At the
end of the 72-hour drug release period, it could be seen that the cumulative drug release ratio
climbed to an overwhelming 88.82 % at pH 5.0 while a minimal release of 14.78 % was recorded
at pH 7.4 (Figure 35). This ratio shows that the GEM release rate in non-covalent FA-CDs-GEM
is 6 times higher in acid than neutral conditions. Overall, the results indicate that non-covalent
FA-CDs-GEM-HC might have the potential to deposit more GEM drugs at the cancer sites.
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Figure 37. A graph showing the pH-responsive release of GEM from non-covalent FA-CD-GEM
in PBS buffer at pH 5.0 and 7.4.
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Cytotoxicity Study
A standard MTT assay was conducted by Dr. Victoria Palau at the Gatton College of
Pharmacy. This was done after the in vitro drug release assessment to ascertain the cytotoxic
effects of the engineered FA-CD-DOX NPs on two different cancer lines. The less aggressive
MDA-MB-468 breast cancer cell line was cultured with low folate receptor (FR) expression
while the more aggressive MDA-MB-231 cancer cell line was cultured with high FR expression.
This was a necessary step to improve targetability as well as drug delivery to the cancer cells.
Generally, the MTT assay works by measuring the mitochondrial activity via the conversion of
MTT into formazan crystals by viable cells. Here, an increase or decrease in formazan
concentration is measured spectrophotometrically at an optical density (OD) of 540 nm and 720
nm using a plate reader. The % cell viability is then calculated using the equation; % cell
viability = mean OD treated cells/mean OD control x 100. Using this treatment, the non-covalent
FA-CD-DOX NPs were tested against the MDA-MB-468 and MDA-MB-231 cancer cell lines.
As shown in Figure 38, a significant reduction in % cell viability was measured when the more
aggressive MDA-MB-231 cancer cell was incubated with the FA-CD-DOX NPs compared to the
less aggressive MDA-MB-468 cell line. This means that the FA-CD-DOX NPs were better
internalized in the cells with overexpressed FR, leading to the high accumulation of DOX and an
overall improved therapeutic efficacy. The result also correlates with the in vitro drug release
assessment and proves the targeting ability of FA. Thus, the non-covalent FA-CD-DOX NPs
could work as efficient theranostic NPs to detect and treat cancer.
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Figure 38. Cell viability of MDA-MB-468 and MDA-MB-231 breast cancer cell lines at 72 h
using the MTT assay.
Photostability Studies
The photostability studies were performed on CDs and FA-CDs NPs to determine any
changes in fluorescence intensity as well as the best storage conditions. The samples were kept at
room temperature (25 – 30 oC) and at 5 oC for 8 months after which they were separately
observed under a UV lamp. As shown in Figure 39 (A and B), it could be observed that the
fluorescence intensity dropped significantly after 8 months of storage under room temperature.
The CDs sample lost the bright blue fluorescent intensity and developed a musky green color in
the process while the FA-CDs solution has a significantly low blue fluorescence intensity. These
results indicate that refrigerating temperature (5 oC) is best storage condition for CDs and FACDs NPs due to increased aggregation-state fluorescence under these conditions.102
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(A)

(B)

Figure 39. A digital photo of (A) CDs and (B) FA-CDs under refrigeration and room temperature
storage conditions viewed under a 4-watt, 365 nm UVGL-15 compact UV lamp.
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CHAPTER 4. CONCLUSION AND FUTURE WORK
In conclusion, both covalent and non-covalent CDs-DOX/FA-CDs-DOX-HC and CDsGEM/FA-CDs-GEM-HC NPs were successfully prepared in the lab and were further
characterized using UV–Vis, FL and FTIR spectroscopy. The electrostatic binding of DOX and
GEM in the non-covalent CDs-DOX/FA-CDs-DOX-HC and CDs-GEM/FA-CDs-GEM-HC NPs
was confirmed by agarose gel electrophoresis. It was found that CDs are negatively charged
while DOX and GEM are positively charged thereby facilitating the electrostatic interaction.
Also, photostability studies showed that CDs and FA-CDs NPs are best kept under refrigerating
(5 oC) conditions to maintain their fluorescence. Furthermore, assessment of the DLC and DLE
with UV–Vis indicated that the non-covalent NPs have low DLC but high DLE compared to the
relatively low DLE and high DLC of covalent NPs. In vitro drug release studies revealed that the
DOX and GEM release rate was faster in the non-covalent FA-CDs-DOX/GEM-HC NPs than
their covalent counterparts. Also, the non-covalent FA-CDs-DOX-HC NPs showed a greater %
CDR and lower cell viability in MDA-MB-231 compared to the covalent complexes. This new
FA-CDs-DOX NPs could work as efficient theranostic systems to detect and treat cancer. In the
future, we will concentrate on the cytotoxicity studies of non-covalent CDs-GEM/FA-CDsGEM-HC NPs on MD-MBA-231 cancer cell lines. Moreover, attempts will be made to
synthesize covalent and non-covalent triple conjugate (FA-CDs-DOX-GEM) system in efforts to
achieve combinational therapy.
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APPENDICES
Appendix A: Drug Release Tables
Table A.1. Release of Gemcitabine from Non-covalent FA-CD-GEM-HC at pH 5.0
Serial No.

Time (h)

Absorbance

Concentration

Amount of

% CDR at

(µg/mL)

Drug (µg)

pH 5.0

1

1

0.026

0.55

55

5.5

2

2

0.031

0.76

76

7.6

3

3

0.064

2.11

211

21.1

4

18

0.112

4.08

408

40.8

5

22

0.163

6.17

617

61.7

6

46

0.215

8.31

831

83.1

7

72

0.229

8.88

888

88.8
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Table A.2. Release of Gemcitabine from Non-covalent FA-CD-GEM-HC at pH 7.4
Serial No.

Time (h)

Absorbance

Concentration

Amount of

% CDR at

(µg/mL)

Drug (µg)

pH 7.4

1

1

0.015

0.12

12

1.2

2

2

0.019

0.29

29

2.9

3

3

0.024

0.49

49

4.9

4

18

0.028

0.66

66

6.6

5

22

0.035

0.94

94

9.4

6

46

0.041

1.40

140

14.0

7

72

0.048

1.48

148

14.8
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Table A.3. Release of Doxorubicin from Covalent FA-CD-DOX at pH 5.0
Serial No.

Time (h)

Absorbance

Concentration

Amount of

% CDR at

(µg/mL)

Drug (µg)

pH 5.0

1

1

0.022

1.25

125

12.5

2

2

0.029

1.67

167

16.7

3

3

0.035

2.03

203

20.3

4

18

0.062

3.65

365

36.5

5

22

0.084

4.96

496

49.6

6

46

0.120

7.12

712

71.2

7

72

0.145

8.62

862

86.2
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Table A.4. Release of Doxorubicin from Covalent FA-CD-DOX at pH 7.4
Serial No.

Time (h)

Absorbance

Concentration

Amount of

% CDR at

(µg/mL)

Drug (µg)

pH 7.4

1

1

0.009

0.47

47

4.7

2

2

0.015

0.83

83

8.2

3

3

0.017

0.95

95

9.4

4

18

0.021

1.19

119

11.9

5

22

0.024

1.37

137

13.7

6

46

0.027

1.55

155

15.5

7

72

0.029

1.67

167

16.7
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Appendix B: Calculation of %DLC and %DLE
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Figure B.1. UV–Vis spectrum of non-covalent CDs-DOX before dialysis.
Non-covalent CDs-DOX
1. Calculation of the mass of DOX used
In the conjugation reaction, 2.00 mg (2.00 mL of a 1.00 mg/mL solution) of DOX-HCl
was used.
From the molecular weights of DOX (543.53 g/mol) and DOX-HCl (579.98 g/mol), the
mass of DOX used is calculated as:
2.00 mg * (543.53/579.98) = 1.874 mg.
2. Calculation of the mass of DOX unconjugated to CDs
After conjugation, the CDs-DOX were dialyzed, and the dialysate was analyzed for free
DOX by UV–Vis spectroscopy after dilution of a 0.200 mL aliquot to 1.00 mL.
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From the calibration curve for DOX (Figure 33),
A485 = c*16.678 − 0.0012

(B.1)

Where c is the concentration of DOX in mg/mL.
For the diluted sample, A485 was 0.085.
Therefore, c = (0.085 + 0.0012)/16.678 = 0.00517 mg/mL = 5.17 µg/mL
Multiplying by the volume of dialysate (2.90 mL) and the dilution factor of 5 affords a
mass of 0.0750 mg of DOX unconjugated.
3. Calculation of the mass of DOX unconjugated to CDs
Subtraction of the unconjugated mass of 0.0750 mg from the initial mass of 1.874 mg
affords a total of 1.799 mg of DOX conjugated
4.

Calculation of %DLC
The DOX was conjugated to 8.00 mg of CDs, affording a total mass of 9.799 mg of
DOX-CDs.
%DLC = 100*(1.799 mg of DOX)/(9.799 mg of CDs-DOX) = 18.4%

5. Calculation of %DLE
%DLE = 100*(1.799 mg of DOX conjugated)/(1.874 mg of DOX used) = 96.0%
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Non-covalent FA-CDs-DOX
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Figure B.2. UV–Vis spectrum of non-covalent FA-CDs-DOX before dialysis.

1. Calculation of the mass of DOX used
In the conjugation reaction, 2.00 mg (2.00 mL of a 1.00 mg/mL solution) of DOX-HCl
was used.
From the molecular weights of DOX (543.53 g/mol) and DOX-HCl (579.98 g/mol), the
mass of DOX used is calculated as:
2.00 mg * (543.53/579.98) = 1.874 mg.
2. Calculation of the mass of DOX unconjugated to FA-CDs
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After conjugation, the FA-CDs-DOX were dialyzed, and the dialysate was analyzed for
free DOX by UV–Vis spectroscopy after dilution of a 0.200 mL aliquot to 1.00 mL.
From the calibration curve for DOX (Figure 33),
A485 = c*16.678 − 0.0012

(B.2)

Where c is the concentration of DOX in mg/mL.
For the diluted sample, A485 was 0.090.
Therefore, c = (0.090 + 0.0012)/16.678 = 0.00546 mg/mL = 5.46 µg/mL
Multiplying by the volume of dialysate (2.90 mL) and the dilution factor of 5 affords a
mass of 0.0793 mg of DOX unconjugated.
3. Calculation of the mass of DOX unconjugated to FA-CDs
Subtraction of the unconjugated mass of 0.0793 mg from the initial mass of 1.874 mg
affords a total of 1.795 mg of DOX conjugated
4.

Calculation of %DLC
The DOX was conjugated to 8.00 mg of FA-CDs, affording a total mass of 9.799 mg of
FA-CDs-DOX.
%DLC = 100*(1.795 mg of DOX)/(17.7947 mg of FA-CDs-DOX) = 10.08%

5. Calculation of %DLE
%DLE = 100*(1.795 mg of DOX conjugated)/(1.874 mg of DOX used) = 95.77%
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Covalent CDs-GEM
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Figure B.3. UV–Vis spectrum of covalent CDs-GEM before dialysis.

1. Calculation of the mass of GEM used
In the conjugation reaction, 1.5.00 mg (1.00 mL of a 1.50 mg/mL solution) of GEM-HCl
was used.
From the molecular weights of GEM (263.2 g/mol) and GEM-HCl (299.7 g/mol), the
mass of GEM used is calculated as:
1.50 mg * (263.2/299.7) = 6.587 mg.
2. Calculation of the mass of GEM unconjugated to CDs
After conjugation, the CDs-GEM were dialyzed, and the dialysate was analyzed for free
GEM by UV–Vis spectroscopy after dilution of a 0.200 mL aliquot to 1.00 mL.
From the calibration curve for DOX (Figure 32),
A485 = c*24.363 + 0.0126
134

(B.3)

Where c is the concentration of GEM in mg/mL.
For the diluted sample, A269 was 1.705.
Therefore, c = (1.705 − 0.0126)/24.363 = 0.06947 mg/mL = 69.47 µg/mL
Multiplying by the volume of dialysate (3.70 mL) and the dilution factor of 5 affords a
mass of 1.285 mg of GEM unconjugated.
3. Calculation of the mass of GEM unconjugated to CDs
Subtraction of the unconjugated mass of 1.285 mg from the initial mass of 6.587 mg
affords a total of 5.301 mg of GEM conjugated
4.

Calculation of %DLC
The GEM was conjugated to 8.00 mg of CDs, affording a total mass of 15.1 mg of CDsGEM.
%DLC = 100*(5.301 mg of GEM)/(15.1 mg of CDs-GEM) = 35.11%

5. Calculation of %DLE
%DLE = 100*(5.301 mg of GEM conjugated)/(6.587 mg of GEM used) = 80.49%
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Covalent FA-CDs-GEM
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Figure B.4. UV–Vis spectrum of covalent FA-CDs-GEM before dialysis.

1. Calculation of the mass of GEM used
In the conjugation reaction, 1.5.00 mg (1.00 mL of a 1.50 mg/mL solution) of GEM-HCl
was used.
From the molecular weights of GEM (263.2 g/mol) and GEM-HCl (299.7 g/mol), the
mass of GEM used is calculated as:
1.50 mg * (263.2/299.7) = 6.587 mg.
2. Calculation of the mass of GEM unconjugated to FA-CDs
After conjugation, the FA-CDs-GEM were dialyzed, and the dialysate was analyzed for
free GEM by UV–Vis spectroscopy after dilution of a 0.200 mL aliquot to 1.00 mL.
From the calibration curve for DOX (Figure 32),
A485 = c*24.363 + 0.0126
Where c is the concentration of GEM in mg/mL.
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(B.4)

For the diluted sample, A269 was 1.085.
Therefore, c = (1.085 − 0.0126)/24.363 = 0.04402 mg/mL = 44.02 µg/mL
Multiplying by the volume of dialysate (3.80 mL) and the dilution factor of 5 affords a
mass of 0.836 mg of GEM unconjugated.
3. Calculation of the mass of GEM unconjugated to FA-CDs
Subtraction of the unconjugated mass of 0.836 mg from the initial mass of 6.587 mg
affords a total of 5.751 mg of GEM conjugated
4.

Calculation of %DLC
The GEM was conjugated to 16.00 mg of FA-CDs, affording a total mass of 21.751 mg
of CDs-GEM.
%DLC = 100*(5.751 mg of GEM)/(21.751 mg of FA-CDs-GEM) = 26.44%

5. Calculation of %DLE
%DLE = 100*(5.751 mg of GEM conjugated)/(6.587 mg of GEM used) = 87.31%
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Covalent CDs-DOX
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Figure B.5. UV–Vis spectrum of covalent CDs-DOX before dialysis.

Covalent CDs-DOX
1. Calculation of the mass of DOX used
In the conjugation reaction, 7.50 mg (1.50 mL of a 5.00 mg/mL solution) of DOX-HCl
was used.
From the molecular weights of DOX (543.53 g/mol) and DOX-HCl (579.98 g/mol), the
mass of DOX used is calculated as:
7.50 mg * (543.53/579.98) = 7.028 mg.
2. Calculation of the mass of DOX unconjugated to CDs
After conjugation, the CDs-DOX were dialyzed, and the dialysate was analyzed for free
DOX by UV–Vis spectroscopy after dilution of a 0.200 mL aliquot to 1.00 mL.
From the calibration curve for DOX (Figure 33),
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A485 = c*16.678 − 0.0012

(B.5)

Where c is the concentration of DOX in mg/mL.
For the diluted sample, A485 was 0.840.
Therefore, c = (0.840 + 0.0012)/16.678 = 0.05044 mg/mL = 50.44 µg/mL
Multiplying by the volume of dialysate (3.80 mL) and the dilution factor of 5 affords a
mass of 0.958 mg of DOX unconjugated.
3. Calculation of the mass of DOX unconjugated to CDs
Subtraction of the unconjugated mass of 0.958 mg from the initial mass of 7.028 mg
affords a total of 6.070 mg of DOX conjugated
4.

Calculation of %DLC
The DOX was conjugated to 8.00 mg of CDs, affording a total mass of 14.07 mg of
DOX-CDs.
%DLC = 100*(6.070 mg of DOX)/(14.07 mg of CDs-DOX) = 43.14%

5. Calculation of %DLE
%DLE = 100*(6.070 mg of DOX conjugated)/(7.028 mg of DOX used) = 86.4%
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Figure B.6. UV–Vis spectrum of covalent FA-CDs-DOX before dialysis.

1. Calculation of the mass of DOX used
In the conjugation reaction, 7.50 mg (1.50 mL of a 5.00 mg/mL solution) of DOX-HCl
was used.
From the molecular weights of DOX (543.53 g/mol) and DOX-HCl (579.98 g/mol), the
mass of DOX used is calculated as:
7.50 mg * (543.53/579.98) = 7.028 mg.
2. Calculation of the mass of DOX unconjugated to FA-CDs
After conjugation, the FA-CDs-DOX were dialyzed, and the dialysate was analyzed for
free DOX by UV–Vis spectroscopy after dilution of a 0.200 mL aliquot to 1.00 mL.
From the calibration curve for DOX (Figure 33),
A485 = c*16.678 − 0.0012
Where c is the concentration of DOX in mg/mL.
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(B.6)

For the diluted sample, A485 was 0.411.
Therefore, c = (0.411 + 0.0012)/16.678 = 0.02472 mg/mL = 24.72 µg/mL
Multiplying by the volume of dialysate (3.70 mL) and the dilution factor of 5 affords a
mass of 0.45723 mg of DOX unconjugated.
3. Calculation of the mass of DOX unconjugated to FA-CDs
Subtraction of the unconjugated mass of 0.45723 mg from the initial mass of 7.028 mg
affords a total of 6.571 mg of DOX conjugated
4.

Calculation of %DLC
The DOX was conjugated to 16.00 mg of FA-CDs, affording a total mass of 22.571 mg
of DOX-CDs.
%DLC = 100*(6.571 mg of DOX)/(22.571 mg of FA-CDs-DOX) = 29.11%

5. Calculation of %DLE
%DLE = 100*(6.571 mg of DOX conjugated)/(7.028 mg of DOX used) = 93.50%
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